



BOX PCT

Commissioner for Patents  
Washington, D.C. 20231

March 29, 2002

PCT/JP00/06804  
-filed September 29, 2000

10-089600  
JC10 Rec'd PCT/JP00/06804 MAR 2002  
1600 Pennsylvania Avenue, N.W.  
Washington, DC 20037-3493  
T 202.293.7060  
F 202.293.7860

www.sughrue.com

Re: Application of Kei YAMANA, Yukimi NAGASAWA, Hitoshi WADA and Yoshinori KASAHARA  
A NOVEL POLYPEPTIDE AND GENE ENCODING THE SAME  
Assignee: **TEIJIN LIMITED**  
Our Ref: Q69170

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. § 371 and in accordance with Chapter II of the Patent Cooperation Treaty:

- ☒ an executed Declaration and Power of Attorney.
- ☒ an English translation of the International Application.
- ☒ ten (10) sheets of drawings.
- ☒ an executed Assignment and PTO 1595 form.
- ☒ twenty (20) pages of Sequence listing and a 3.5" disk containing Sequence Listing.
- ☒ Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821-1.825.
- ☒ International Search Report, Information Disclosure Statement a Form PTO-1449.

It is assumed that copies of the International Application, the International Search Report, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by § 371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned can easily provide them upon request.

Applicants note that the second inventor's name changed from Yukimi Takahashi to Yukimi Nagasawa due to marriage. A Declaration is being prepared in this regard and will be filed with a Petition after it is executed.

The Government filing fee is calculated as follows:

Total claims	69	-	20	=	49	x	\$18.00	=	\$882.00
Independent claims	6	-	3	=	3	x	\$84.00	=	\$252.00
Base Fee									\$890.00
Multiple Dependent Claim Fee									\$280.00
<b>TOTAL FILING FEE</b>									<b>\$2304.00</b>
Recordation of Assignment									\$40.00
<b>TOTAL FEE</b>									<b>\$2344.00</b>

Checks for the statutory filing fee of \$2304.00 and Assignment recordation fee of \$40.00 are attached. You are also directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.492 which may be required during the entire pendency of the application to Deposit Account No. 19-4880. A duplicate copy of this transmittal letter is attached.

Priority is claimed from:

Country	Application No	Filing Date
Japan	11-275947	September 29, 1999

Respectfully submitted,

*Susan J. Mack* / *Bruce E. Kean*  
Susan J. Mack / Reg. No. 33725  
Registration No. 30,951

SJM/amt

10/PRTS

## Description

A Novel polypeptide and gene encoding the same

## 5 Field of the Invention

The present invention relates to a novel human, mouse and rat polypeptide having a homology in the amino acid sequence with chondromodulin-I (ChM-I) that is known to have an effect of controlling the growth and differentiation of chondrocytes and inhibiting angiogenesis, and a human, mouse and rat gene (hereinafter referred to as "ChM1L gene") encoding the same.

## 15 Background Art

Almost all the bones of mammals are formed through a mechanism called "endochondral bone formation" in which chondrocytes calcify via the growth and differentiation thereof, and are finally replaced with bone. It is known that a variety of hormones and growth factors participate in this series of process, including insulin-like growth factor (IGF1, IGF2), fibroblast growth factor (FGF), transforming growth factor (TGF), growth hormone and the like. Hiraki et al. isolated ChM-I gene as a factor, in addition to the above hormones and growth factors, that facilitates the growth and differentiation of chondrocytes (Biochem. Biophys. Res. Commun., 175, 971-977, 1991, European Patent Publication No. 473080). Human ChM-I is synthesized as a type II membrane protein comprising 334 amino acid residues and, after glycosylation, undergoes processing with a result that the C-terminal portion comprising 120 amino acid residues are extracellularly secreted (Hiraki et al., Eur. J. Biochem. 260, 869-878, 1999). ChM-I not only promotes the growth of cultured chondrocytes but potentially promotes proteoglycan synthesis and the colony formation of chondrocytes in agarose (Inoue et al., Biochem. Biophys.

- 2 -

Res. Commun., 241, 395-400, 1997). ChM-I also promotes the growth of osteoblasts (Mori et al., FEBS Letters, 406, 310-314, 1997).

On the other hand, it has long been pointed out that cartilage remains not only avascular but resistant to infiltration of blood vessels. Hiraki et al. attempted to purify a growth inhibiting factor for vascular endothelial cells from the extracts of cartilaginous tissue, and have succeeded in the complete purification thereof. As a result, it was found to be ChM-I (Hiraki et al., FEBS Letters, 415, 321-324, 1997; Hiraki et al., J. Biol. Chem., 272, 32419-32426, 1997). Generally, the cartilaginous tissue is characterized by being avascular, but in the replacement to the bone tissue, it is believed, infiltration of blood vessels into the cartilaginous tissue is required. In the scheduled region of vascular invasion, the hypertrophy of cartilaginous tissue and the calcification of cartilage matrix occur prior to vascular invasion to be ready for forming the primary point of ossification. In the region where the hypertrophic cartilage and the subsequent ossified cartilage appear, the expression of ChM-I dramatically decreases. Thus, although the expression of the ChM-I gene is cartilage-specific, it is limited to the avascular cartilage that is resistant to vascular invasion. As described above, it is believed that ChM-I not only promotes the growth, differentiation, and maturing of cartilage but inhibits the infiltration of blood vessels by inhibiting the growth of vascular endothelial cells. Thus, the expression in the avascular cartilage and the disappearance of expression in the ossified layer prior to vascular invasion are in good agreement with the bifunctional effect of ChM-I.

In the cartilaginous tissue, bFGF that is a potent angiogenic factor is accumulated in pericellular space in large quantities, and it has been elucidated that ChM-I is present in interterritorial space in such a way as to

- 3 -

surround bFGF (Hiraki et al., J. Biol. Chem., 272, 32419-32426, 1997). Thus, in the avascular cartilage, ChM-I is present in a form that masks the angiogenic factor, and it is thought that the angiogenenic effect of ChM-I may account for the absence of blood vessels in the cartilage (Tanpakusitsu kagaku koso, Vol. 40, No. 5, 1995). It has also been confirmed that ChM-I suppresses the growth of tumor cells by inhibiting the infiltration of blood vessels into human tumor cells in vivo (Hayami et al., FEBS Letters, 458, 436-440, 1999). The expression analysis of ChM-I in various mouse tissues revealed that ChM-I is expressed in the eye and the thymus in addition to the cartilage, but the function of ChM-I in these tissues has yet to be elucidated (Shukunami et al., Int. J. Dev. Biol. 43, 39-49, 1999).

The growth and the expression of differentiation function of chondrocytes plays an important role in the healing process from fracture or various cartilage diseases. Thus ChM-I, a factor that promotes the growth and differentiation of chondrocytes, is a promising candidate for an agent that promotes the growth of chondrocytes (Kokai (Japanese Unexamined Patent Publication) No. 7-138295). In the growth or metastasis of tumor cells, infiltration of blood vessels into tissues is required to obtain energy necessary therefor. Therefore ChM-I that has an effect of inhibiting angiogenesis is also a likely candidate for an anti-cancer agent (Kokai (Japanese Unexamined Patent Publication) No. 7-138295). As described above, ChM-I not only controls the growth and differentiation of chondrocytes but inhibits angiogenesis, and hence its application into drugs is being awaited.

In recent years, biotechnology has made rapid progress, and in association with the development of the human genome project as well, a great number of new genes are being cloned. It is said that the number of human genes amounts to about 100,000, and among the genes

groups of molecules having a homology in the amino acid sequences sometimes form families. As the groups of molecules having a homology in the amino acid sequences, various gene families are known such as the TNF family, the TNF receptor family, the chemokine family, G-protein coupled receptor family and many other gene families. For example, as the molecules belonging to the TNF family, there are known about 20 molecules including tumor necrosis factor  $\alpha$  (TNF $\alpha$ , Pennica et al., Nature 312, 724, 1984), Fas ligand (FasL, Suda et al., Cell 75, 1167, 1993), TNF-related apoptosis-inducing ligand (TRAIL, Steven et al., Immunity 3, 673, 1995), B lymphocyte stimulator (BLYS, Moore et al., Science 285, 260-263, 1999), and the like.

The molecules belonging to the TNF family are type II membrane proteins and have a homology in the amino acid sequence in the extracellular region. Although homology in the amino acid sequence is noted, these molecules have been demonstrated to have their inherent functions, and their application as pharmaceutical agents have been attempted in a variety of diseases. It has also been shown that the molecules of the TNF family have their unique receptors, and the application thereof as pharmaceutical agents have also been attempted. In fact, some have been approved as pharmaceutical products (for example, soluble TNF receptor, by Immunex). Research and development is also in progress on antibodies against these molecules as pharmaceutical drugs, and in fact, some have been approved as pharmaceutical products (for example, anti-TNF- $\alpha$  antibody, by Centocore). As examples of molecules having a homology in the amino acid sequence that were applied into the development of pharmaceutical products, the TNF family and the TNF receptor family were illustrated as above. Some of the underlying reasons that enabled the application of these molecules into pharmaceutical products are the facts that

- 5 -

the functions of each of these molecules were analyzed and the similarity and the difference between them were elucidated.

5 Molecules of the TNF family have the structure of type II membrane proteins and since many of them are expressed mostly in the blood system and the lymphatic system, they have a lot in common in terms of experimental techniques and samples. It is therefore expected that when a new gene belonging to the TNF family  
10 was discovered, the speed at which its function was analyzed must have been faster than the molecules discovered earlier. Thus, the discovery of a novel gene having a homology in the amino acid sequence and the analysis of its function would not only facilitates the  
15 functional analysis of novel genes to be discovered in the future but the result of analysis permits its comparison with the existing molecules, and therefore it is expected that more detailed findings on the functions of the existing molecules could be obtained.

20 Generally, when a novel gene encoding a protein having a homology in the amino acid sequence with existing molecules is cloned, the techniques and materials to be used for functional analysis may be referred to the examples of the existing molecules.  
25 However, even a molecule having a homology in the amino acid sequence is thought to have its own unique function as in the above-mentioned TNF family, and thus when its application into pharmaceutical products is envisaged, it is necessary to demonstrate the expression and  
30 purification of the recombinant protein, the generation of antibody, the expression of mRNA and protein at various tissues and the like, and thereby to clarify the difference in the structure and function from the existing molecules.

35

Disclosure of the Invention

Thus, it is an object of the present invention to

- 6 -

provide a new polypeptide similar to ChM-I and a gene encoding the same. It is also an object of the present invention to implement the generation of antibody against said polypeptide, the analysis of expression levels of said gene and the polypeptide, the expression and structural analysis of the recombinant protein and the like in order to clarify its similarity and difference with ChM-I, and to elucidate the function so as to enable the elucidation of pathological states, diagnosis, treatment etc. of diseases in which they are involved.

ChM-I is a type II membrane protein that regulates the growth and differentiation of chondrocytes and inhibits angiogenesis, and is a promising candidate for application into pharmaceutical products. Thus, once a gene encoding a new polypeptide similar to ChM-I has been provided, it is believed, its expression level in various cells and its structure and function can be analyzed, and the analysis of the expression products would enable the elucidation of pathology, diagnosis and treatment etc. of diseases in which they are involved. At present, however, there are no reports on molecules having a homology with the amino acid sequence of ChM-I, and it is unknown whether ChM-I forms a gene family or not. Thus, if a new polypeptide similar to ChM-I and a gene encoding the same are shown to be present, the analysis of structure, function etc. thereof would permit the study on its similarity and difference with ChM-I, which in turn would accelerates the elucidation of physiological functions of the molecules with one another, the elucidation of pathological states in which these molecules are involved, diagnosis, the development of therapeutic agents and the like.

After intensive and extensive research to attain the above purposes, the inventors of the present invention have succeeded in isolating a gene (ChM1L gene) that meets the above purposes, from human, mouse and rat cDNA libraries, and carried out the analysis of its expression

- 7 -

level in various tissues, the generation of an antibody against said polypeptide, the expression of a polypeptide encoded by said gene in a mammalian cell, its detection and purification and the like, demonstrating that said  
5 polypeptide has an effect of inhibiting angiogenesis, and we hereby have completed the present invention.

Thus, the present invention is a gene encoding a polypeptide that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 2, 4, and 6. As the  
10 above gene, there can be mentioned the nucleotide sequence represented by SEQ ID NO: 1, 3, and 5.

Furthermore, the present invention is a polypeptide encoded by a human, mouse and rat gene which polypeptide substantially comprises the amino acid sequence as set  
15 forth in SEQ ID NO: 2, 4 and 6.

The present invention is also an oligonucleotide probe that hybridizes to at least part of the above gene.

The present invention is also a recombinant DNA comprising the above gene.

20 The present invention is also a transformant transformed with the above recombinant DNA.

The present invention is also a method of producing the above polypeptide which method comprises culturing the above transformant and harvesting a polypeptide  
25 encoded by the gene of the present invention from the culture.

The present invention is also a monoclonal antibody or polyclonal antibody that specifically reacts with the above polypeptide.

30 The present invention is also a hybridoma that produces the above monoclonal antibody that is obtained by fusing an antibody-producing cell immunized with the above polypeptide to a myeloma cell.

The present invention is also a reagent for  
35 detecting genes said reagent comprising the above oligonucleotide probe.

The present invention is also a diagnostic kit that



- 8 -

comprises the above polypeptide and the above monoclonal antibody or polyclonal antibody.

5       The present invention is also a pharmaceutical composition comprising a polypeptide encoded by the gene that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 2, 4, or 6.

10       The present invention is also a pharmaceutical composition comprising a monoclonal antibody or a polyclonal antibody that specifically reacts with the above polypeptide.

      The present invention is also a pharmaceutical composition comprising an antisense oligonucleotide that specifically hybridizes to part of the above gene.

15       The present invention is also a pharmaceutical composition comprising a nucleic acid that can be used in gene therapy said composition comprising at least part of the above gene.

      The present invention is also a polypeptide wherein the above polypeptide is a membrane-bound form.

20       The present invention is also a gene encoding the above membrane-bound polypeptide.

      The present invention is also a gene wherein the above human gene is present on chromosome X.

25       The present invention is also a polypeptide wherein the above polypeptide has an effect of inhibiting angiogenesis.

      The present invention is also a gene encoding the above polypeptide that has the above effect of inhibiting angiogenesis.

30

#### Brief Explanation of the Drawings

      Figure 1A is a result in which the homology of amino acid sequences of human ChM1L and human ChM-I were compared.

35       Figure 1B is a result in which the homology of amino acid sequences of human, mouse and rat ChM1L were compared.



- 10 -

Figure 7 shows the result in which the expression of ChM1L protein in mouse rib cartilage was detected by immunostaining using anti-ChM1L polypeptide antibody.

5 Figure 8 shows the result in which a soluble human ChM1L protein that was expressed in the culture liquid of COS7 cells was purified by affinity chromatography using anti-FLAG M2 affinity gel, electrophoresed, and stained with Coomassie brilliant blue. Lane 1 shows the result of electrophoresis of the culture supernatant of COS7  
10 cells and lane 2 shows that of the purified ChM1L protein.

Figure 9 shows the result in which the tube-like structure-forming system of the human umbilical vein endothelial cells were treated with (a) the buffer alone,  
15 (b) 20  $\mu$ g of bovine serum albumin (BSA), (c) 10  $\mu$ g of soluble human ChM1L, (d) 20  $\mu$ g of soluble human ChM1L, (e) 1  $\mu$ g of platelet factor 4 (PF-4), and (f) 10  $\mu$ g of PF-4.

## 20 Best Mode for Carrying Out the Invention

In accordance with the present invention, "substantially comprise" means that the gene or polypeptide of the present invention, as long as it retains its function, may have mutations such as  
25 substitution, insertion, or deletion in the nucleotide sequence as set forth in SEQ ID NO: 1, 3, or 5 or the amino acid sequence as set forth in SEQ ID NO: 2, 4, or 6.

The ChM1L gene sequence of the present invention may be obtained by the RACE method (RACE: Rapid amplification of cDNA ends; Frohman, M. A. et al., Proc. Natl. Acad. Sci. USA, 85, 8998-9002, 1988), the outline of which method is as follows:

30 Generally, the RACE method enables one to obtain a full-length cDNA in an efficient manner, when a portion of a cDNA sequence is known. Primers are constructed

- 11 -

from known sequence regions to permit elongation in each of the 3'-end or 5'-end direction, and then cDNA is amplified by the polymerase chain reaction (PCR, Science, 230, 1350-1354, 1985). When a PCR method is carried out, 5 primers that specifically anneal are used in the known region, and primers that anneal to the sequence tagged by a ligation reaction are used in the 3'-end and the 5'-end. Thus, the regions amplified by PCR contain unknown regions. The isolation and purification of the amplified 10 cDNA fragment can be performed according to a standard method as described below, for example gel electrophoresis may be employed. The determination of nucleotide sequence of the DNA fragment thus obtained may be performed according to a standard method such as the 15 dideoxy method (Proc. Natl. Acad. Sci. USA, 74, 5463-5467, 1977) and the Maxam-Gilbert method (Methods in Enzymology, 65, 499, 1980). Such determination of nucleotide sequences may also be carried out using commercially available sequencing kits, etc.

20 More specifically, it is outlined as follows, though more detailed explanations thereof will be made hereinafter in Example 2. Using the amino acid sequence of human ChM-I, TBLASTN search was performed for the EST data base (dbEST, EST: Expressed sequence tag) in the DNA 25 data bank of Japan (DDBJ) to detect an EST file, Genbank accession number A1123839. A1123839, which is a nucleotide sequence fragment registered in dbEST, was found for the first time by the above TBLASTN search to be a novel gene fragment encoding an amino acid sequence 30 similar to ChM-I. Thus, primers were synthesized from part of the sequence of cDNA obtained from dbEST, and the sequence of human ChM1L gene was determined using the RACE method. Subsequently, the sequences of mouse and rat ChM1L genes were similarly determined. The sequences 35 of human, mouse and rat ChM1L genes are shown in SEQ ID NO: 1, 3 and 5, and the amino acid sequences of the peptides encoded thereby are shown in SEQ ID NO: 2, 4 and

6.

The polypeptides encoded by the ChM1L genes of the present invention are composed of 317 amino acids (SEQ ID NO: 2, 4 and 6). The amino acid sequence of ChM1L has a homology with ChM-I, in particular a very high homology with the C-terminal portion that is extracellularly secreted after the processing of ChM-I (Figure 1(a)). The amino acid sequences of ChM1L have a very high homology in between humans, mice, and rats (Figure 1(b)). From the hydrophobicity analysis of the amino acid sequence, ChM1L similarly to ChM-I is thought to be a molecule having the structure of the type II membrane proteins (Figure 2). As shown in Figure 2, in both of said polypeptide and ChM-I, a hydrophobic domain comprising about 20 amino acids that is uniquely found in molecules having a membrane-binding activity is present in the vicinity of several dozen amino acids from the N-terminal. That said polypeptide is a molecule having the type II membrane protein structure was also demonstrated by the result in Example 8 in which said polypeptide was expressed in COS7 cells (Figure 4).

The human ChM1L gene of the present invention was shown, as described below in Example 12, to be present on chromosome X (Genbank accession No. AL035608).

As the ChM1L gene of the present invention, there can be mentioned cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA and combinations thereof. Using a standard method, said genomic DNA may also be isolated by hybridization with the ChM1L gene that is disclosed herein. RNA that was transcribed from said ChM1L gene is also encompassed in the present invention. The sequences of the gene of the present invention represented by SEQ ID NO: 1, 3 and 5 are a combination example of codons representing amino acid residues encoded by them. The ChM1L gene of the present invention is not limited to this, and it is also possible to have a DNA sequence obtained by combining codons to amino acid

- 13 -

residues and then selected. The selection of said codon may be performed according to a standard method, and for example the frequency of use of host's codons to be used is taken into account (Nucleic Acids Research, 9, 43-74, 1981).

Furthermore, the ChM1L gene of the present invention encompasses DNA sequences encoding mutants in which parts of the amino acid sequence as set forth in SEQ ID NO: 2, 4, and 6 are substituted, deleted, or added. The production, modification (mutation) and the like of these polypeptides may naturally occur, and can be obtained by post-translational modification or by a genetic engineering method such as site-specific mutagenesis (Methods in Enzymology, 154, 350, 367-382, 1987; *ibid.*, 100, 468, 1983; Nucleic Acids Research, 12, 9441, 1984; Zoku Seikagaku Jikken Koza 1 (Sequel to Biochemistry Experimental Series 1) "Idensi Kenkyuuhou II (Gene Study Method II)", edited by The Japanese Biochemical Society, 105, 1986) and the like.

The production of the ChM1L gene of the present invention may be readily performed by a common genetic engineering method based on the sequence information of the ChM1L gene of the present invention (Molecular Cloning, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989; Zoku Seikagaku Jikken Koza (Sequel to Biochemistry Experimental Series) "Idensi Kenkyuuhou I, II, III (Gene Study Method I, II, III)", edited by The Japanese Biochemical Society, 1986).

This can be attained by, for example, selecting the desired clones from a cDNA library (prepared from a suitable cell source that expresses the ChM1L gene according to a standard method) using suitable probes and antibodies unique to the gene of the present invention (Proc. Natl. Acad. Sci. USA, 78, 6613, 1981; Science, 222, 778, 1983, and the like).

In the above method, as the cell source, there can be illustrated various cells, tissues, and cultured cells

- 14 -

derived therefrom and the like that express the ChM1L gene, from which any of separation of total RNA, separation and purification of mRNA, and conversion (synthesis) into cDNA, cloning etc. may be performed according to a standard method. cDNA libraries are commercially available, and in the present invention, these cDNA libraries such as various cDNA libraries commercially available from Clontech can be used.

The screening of the ChM1L gene of the present invention from a cDNA library may be carried out according to the above standard method. As the above screening method for, for example a polypeptide produced by cDNA, there can be illustrated a method of selecting a corresponding cDNA clone by immunological screening using a specific antibody against a polypeptide encoded by the ChM1L gene of the present invention, a plaque hybridization method using a probe that selectively binds to the nucleotide sequence of interest, a colony hybridization method and the like as well as combinations thereof. Probes that may be used herein include a DNA sequence that was chemically synthesized based on the information on the DNA sequence of the ChM1L gene of the present invention, the ChM1L gene of the present invention that was already obtained and fragments thereof.

In order to obtain the ChM1L gene of the present invention, a PCR method for amplifying DNA/RNA can be preferably used. Primes for use in such a method can be appropriately selected based on the sequence information of the ChM1L gene of the present invention that was elucidated for the first time by the present invention, and can be synthesized according to a standard method.

More specifically, it is outlined as follows, though more detailed explanations thereof will be made hereinafter in Example 2. A primer is synthesized so as to contain the coding sequence of the ChM1L gene, and the it is used to amplify the ChM1L gene using a PCR method.

- 15 -

Then, it is electrophoresed and the band of interest is excised, from which DNA is purified. The purified DNA and the plasmid vector are ligated and transformed into *Escherichia coli* (*E. coli*). Subsequently, the plasmid is  
5 purified from the *E. coli* culture liquid and the integration of the sequence of interest is confirmed using a DNA sequencer. The ChM1L gene thus cloned can be transferred to other plasmid vectors or virus vectors using suitable restriction enzymes.

10 Using the ChM1L gene (cDNA and genomic DNA) thus obtained, it is possible to create a genetically modified animal in which the expression of the ChM1L gene is increased, decreased, or lost by a standard method.

Based on the sequence information of the ChM1L gene  
15 of the present invention, the expression of the ChM1L gene of the present invention in various tissues can be detected using part or all of the nucleotide sequence of said gene. This can be advantageously accomplished according to standard methods such as the RT-PCR (reverse  
20 transcribed-polymerase chain reaction) (Kawasaki, E.S., et al., Amplification of RNA. In PCR Protocol, A Guide to methods and applications, Academic Press, Inc., San Diego, 21-27, 1989) method, Northern blotting analysis (Molecular Cloning, Cold Spring Harbor Laboratory, 1989)  
25 and the like. Primers for the RT-PCR method and probes for Northern blotting analysis are not limited, as long as they are the sequences capable of specifically detecting the ChM1L gene, and such sequences can be appropriately determined based on the nucleotide sequence  
30 of the ChM1L gene of the present invention. Thus, the present invention provides primers and/or probes useful for the detection of the ChM1L gene. The above probes may also be used for the detection of genomic DNA by Southern blotting analysis.

35 As means to detect the expression of ChM1L mRNA, there can be illustrated the RT-PCR method described in Example 6. It is outlined as follows, though more



detailed explanations thereof will be made hereinafter in Example 6.

After extracting each tissue and extracting RNA therefrom, it is subjected to a reverse transcription reaction to synthesize cDNA. Using this cDNA as a template, a PCR reaction is carried out, and the reaction mixture obtained is subjected to electrophoresis on agarose gel. Examining the band under UV irradiation, the amount of the ChM1L gene expressed in each tissue was detected. As a result, the expression of ChM1L mRNA in each tissue of an adult mouse was observed in the brain, the eyeball, the skeletal muscle, the whole rib and the thyroid (Figure 3(a)). On the other hand, the expression of ChM-I mRNA in the mouse has been confirmed in the eyeball, the thymus, the cartilage and the whole rib (Shukunami et al., J. Dev. Biol. 43, 39-49, 1999). Thus, it was revealed that ChM1L and ChM-I are expressed at different tissues in the living body, and thus their physiological functions were considered to be different. The expression of ChM1L was observed even at tissues such as the brain, the skeletal muscle, and the thyroid in which no expression of ChM-I has been confirmed.

Since ChM1L is also expressed in the eyeball that is a tissue in which ChM-I expression has been observed and that is resistant to vascular invasion and the whole rib containing cartilage, ChM1L is thought to be involved in angiogenesis. These results suggest that ChM1L may be associated with brain-related diseases such as Alzheimer's disease, skeletal muscle-related diseases such as muscular dystrophy, thyroid-related diseases such as Basedow's disease, eyeball-related diseases such as diabetic retinopathy, cartilaginous tissue-related diseases such as osteoarthritis and rheumatoid arthritis, and angiogenesis-related diseases such as cancer. Thus, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, agents that promote or

- 17 -

reduce the expression of the ChM1L gene, and the like are considered to be used as therapeutic agents for these diseases. The agonists and antagonists mentioned above are intended to include peptides, proteins, low molecular weight compounds and the like, but the physical properties are not limited to them as long as they retain the function.

In various tissues of a fetus, the expression of ChM1L mRNA was noted in the eyeball, the kidney, the stomach, the whole rib and the trachea (Figure 3(b)). In an adult mouse, ChM1L mRNA was not expressed in the kidney or the stomach, but the ChM1L mRNA was expressed in these tissues of the fetus suggests that ChM1L is involved in the development and morphogenesis of these organs. Thus, ChM1L is thought to be also associated with the repair and regeneration of these organs in adults. It was also revealed that ChM1L mRNA is expressed in the trachea. Thus, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, agents that promote or reduce the expression of the ChM1L gene, and the like are considered to be used as therapeutic agents for kidney-related diseases such as chronic kidney failure, stomach-related diseases such as gastric cancer and gastric ulcer, and trachea-related respiratory diseases such as chronic bronchitis and asthma.

In the developmental stage of the fetus, the expression of ChM1L mRNA is very weak at day 10 of gestation, and the expression increases at around days 11 to 13 (Figure 3(c)). On the other hand, though ChM-I, similarly to ChM1L, increases in expression with the development of the fetus, it was evidently expressed more strongly than ChM1L on days 10 and 11 of gestation. It is, therefore, clear that ChM1L lags behind ChM-I in the expression, and that these molecules have different functions in the development of the fetus. The increase

- 18 -

in ChM1L expression in the developmental stage of the fetus suggests that ChM1L is deeply involved in the generation of organs and the skeleton. Thus, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, agents that promote or reduce the expression of the ChM1L gene, and the like are considered to be used as agents for regenerating and repairing organs in the case of congenital diseases associated with inadequate development of the organs or acquired damages to the organs. Furthermore, since there are differences between ChM1L and ChM-I in the expression in various tissues in the adult and the fetus, and in the expression during the developmental stage of the fetus, it is expected that these molecules and drugs that target these molecules, when used as therapeutic agents, have different uses.

Using the sequence of the ChM1L gene of the present invention, it is possible to produce a polypeptide encoded by said gene by a gene engineering method.

The production of the above polypeptide may be performed by constructing a recombinant DNA that permits the expression of the ChM1L gene of the present invention in a host cell, introducing this into a host cell to transform it and then cultivating said transformant.

As the host cell, any of eukaryotic cells and prokaryotic cells can be used.

As the above eukaryotic cells, there may be mentioned vertebrates, yeasts, insect cells, and the like. As the vertebrate cells, there may be mentioned CHO cells, COS cells, and the like.

As the expression vector for vertebrates, there can be used those that have a promoter generally located upstream of the gene to be expressed, a polyadenylation site, a transcription termination sequence, and the like. As the above expression vector, for example there can be illustrated pSV2dhfr (Mol. Cell. Biol., 854, 1981),

- 19 -

pcDNA3.1(+) (Invitrogen) and pCAGGS (Gene, 108, 193-200, 1991) that have the SV40 early promoter.

As means to express the polypeptide of interest in a eukaryotic cell, there are many systems known per se in the field of art.

For example, as a system that allows expression in yeasts, there can be mentioned "Expression of polypeptides in yeast" described in Kokai (Japanese Unexamined Patent Publication) No. 57-159489, as a system that allows expression in insect cells, there can be mentioned "Process for producing a recombinant baculovirus expression vector" described in Kokai (Japanese Unexamined Patent Publication) No. 60-37988, and as a system that allows expression in mammalian cells, there can be mentioned "Improvement of eukaryotic expression" described in Kokai (Japanese Unexamined Patent Publication) No. 2-171198, and there are many others.

The ChM1L gene of the present invention can also be expressed in prokaryotic host cells such as E. coli, Bacillus subtilis, and Streptomyces. For E. coli as above host cell, Escherichia coli strain K12 is often used, and as the vector pBR322 and improved vectors thereof are often used, but they are not limiting and many other known microbial stains and vectors may be used. As the promoter, for example, there can be mentioned, but not limited to, promoters such as E. coli lactose (lac) and E. coli trp. All of the above promoters have already been characterised and are well known to a person skilled in the art, and can be assembled either synthetically or from known plasmids.

The illustrated DNA sequence of the present invention, plasmids and viruses may have many modifications and variations. For example, due to degeneracy of genetic code, nucleotide substitution can be made throughout the coding region of a polypeptide. Such a sequence can be easily deduced from the nucleotide

- 20 -

sequence of ChMIL gene of the present invention or the amino acid sequence encoded by the gene, and can be assembled by a conventional synthetic method described below. Such a synthetic method may be substantially  
5 carried out according to Itakura's method (Itakura et al., Science, 198, 1059, 1977) and Crea's method (Crea et al., Proc. Natl. Acad. Sci. USA 75, 5765, 1978). Thus the present invention is not limited to the specifically illustrated nucleotide sequences, plasmids or viruses.

10 As methods of introducing the desired recombinant DNA of the present invention into a host cell and the following transforming method, various conventional methods may be used. The transformant obtained may be cultured according to a standard method, from which  
15 culture the polypeptide encoded by the ChMIL gene of the present invention can be produced. As the culture medium used for this culturing, a commonly used medium may be selected as appropriate depending on the host cell adopted, and culturing may be carried out under a  
20 condition suitable for the growth of the host cell.

From the foregoing, the above polypeptide can be produced intracellularly, extracellularly, or on the cell membrane of the transformant. Said polypeptide can be separated and purified utilizing, as desired, the  
25 physical properties, chemical properties thereof or the like by various separation procedures ["Biochemistry Databook II", pp. 1175-1259, First edition, First Print, June 23, 1980, Tokyo Kagaku Dojin; Biochemistry, 25(25), 8274-8277 (1986); Eur. J. Biochem., 163, 313-321 (1987),  
30 and the like]. Specific examples of said methods include, for example, commonly used reconstitution treatment, treatment with a polypeptide precipitating agent (salting out), centrifugation, osmotic shock, ultrasonic disruption, ultrafiltration, gel filtration,  
35 various chromatographic methods such as adsorption chromatography, ion exchange chromatography, affinity chromatography and high performance liquid chromatography

- 21 -

(HPLC), and combinations thereof. Furthermore, by allowing the expression of the protein in which an affinity tag was fused to said polypeptide, the tag can be used to perform affinity purification. As the affinity tag as used herein, there can be mentioned a polyhistidine tag (His tag, Sisk et al., J. Virol., 68, 766, 1994) and a FLAG tag (Hopp et al., Biotechnology 6,, 1204-1210, 1988). The expression and detection of the ChM1L polypeptide fused to these affinity tags can be performed as described in Examples 8 and 9, and it is also possible to purify the ChM1L polypeptide using these tags.

The method of producing the polypeptide encoded by the ChM1L of the present invention is outlined as follows, though more detailed explanations thereof will be made hereinafter in Example 8.

The human and mouse ChM1L gene of the present invention and a gene encoding the ChM1L protein in which a His tag is fused at the C-terminal were cloned into pcDNA3.1(+) vector (Example 4), which was then transfected into COS7 cells. About 48 hours later, the culture supernatant and the cellular components were harvested and were subjected to a Western blot method in order to detect a ChM1L recombinant protein. However, in any of the culture supernatant and the cellular components no expression of ChM1L protein was detected.

Therefore, conditions for detecting the expression of ChM1L recombinant proteins were investigated, and it was found that the use of pCAGGS as the expression vector enables the detection of expression of said polypeptide in COS7 cells. The human and mouse ChM1L gene of the present invention and a gene encoding the ChM1L protein in which a His tag is fused at the C-terminal were cloned into pCAGGS vector (Example 4), which was transfected into COS7 cells. About 48 hours later, the culture supernatant and the cellular components were harvested and were subjected to a Western blot method in order to

detect ChM1L recombinant proteins. No expression of ChM1L recombinant proteins was confirmed in the culture supernatant, whereas in the cellular components two bands were detected at around 40 kDa.

5        Thus, it was revealed that the ChM1L protein is a membrane-bound protein. On the other hand, it has been confirmed that when ChM-I is expressed in COS7 cells, it is secreted as a soluble protein in the culture supernatant (Hiraki et al., J. Biol. Chem., 272, 32419-32426, 1997).  
10        Thus the analysis with COS7 cells revealed that ChM1L and ChM-I are proteins having different structures. That is, it was shown that ChM1L is a cell membrane-bound protein, while ChM-I is a secretory protein, and that the processing mechanisms of these  
15        molecules are different. Among the two bands for the ChM1L protein, the band at the high molecular weight was found to be a form modified by a N-linked sugar chain in the Example 10 described below (Figure 6).

20        The ChM1L protein thus expressed can affinity purified using a ChM1L-specific antibody or an antibody against the tag (His tag) in which 6 residues of histidine are fused, a nickel column and the like.

25        The polypeptide encoded by the ChM1L gene of the present invention may be any of a membrane-bound polypeptide and a soluble polypeptide having no property of binding to the cell membrane. For example, there may be cases in which after the polypeptide is expressed as a membrane-bound polypeptide on the cell membrane, it is cleaved to become a soluble polypeptide. Though the  
30        ChM1L protein was detected as a membrane-bound protein in the expression in COS7 cells (Example 8), it may undergo processing thereby to be a soluble protein when the host cell or the culture condition is different. Furthermore, the soluble polypeptide that lacks the transmembrane  
35        domain can be expressed by fusing a heterologous signal peptide to the N-terminal.

More specifically, the method of expressing the

- 23 -

soluble ChM1L protein is outlined as follows, though more detailed explanations thereof will be made hereinafter in Example 9.

5 A vector was constructed that has integrated, into pCAGGS vector, a nucleotide sequence encoding a protein in which the signal sequence of preprotrypsin, a FLAG tag, the C-terminal end of the extracellular region of ChM1L were fused from the N-terminal end (Example 5).  
10 The ChM1L protein that was expressed using this vector was secreted into the culture liquid as a soluble protein after the signal sequence of preprotrypsin was cleaved (Example 9, Figure 5).

15 The soluble ChM1L polypeptide thus secreted into the culture liquid can be purified using anti-ChM1L antibody or anti-FLAG antibody (Sigma) because a FLAG tag is fused thereto. It is also possible to remove the FLAG tag by cleaving the FLAG fusion protein with enterokinase.

20 More specifically, the method of purifying the soluble ChM1L protein is outlined as follows though more detailed explanations thereof will be made hereinafter in Example 13.

Using a Lipofectamine reagent (GIBCO BRL) according to the instruction attached to the product, pSF-shChM1L was transfected into COS7 cells, and 48 hours later the  
25 culture supernatant was harvested. From this culture supernatant, a soluble ChM1L protein was purified by affinity chromatography using anti-FLAG M2 affinity gel (Sigma) (Figure 8).

30 The ChM1L polypeptide of the present invention can be used as a polypeptide-purifying reagent. Said polypeptide bound to a solid support is very useful for the purification of polypeptides that can bind to said peptide by affinity chromatography. As the polypeptide that can bind to the ChM1L polypeptide, there may be  
35 illustrated soluble polypeptides, membrane-bound polypeptides, antibodies and the like. The soluble ChM1L polypeptide may be readily used for the addition into the



- 24 -

cell culture liquid in vitro, or intravenous administration in vivo.

In order to search the activity of the ChMIL polypeptide of the present invention, human umbilical  
5 vein endothelial cells (HUVECs) were used to analyze the presence of a angiogenesis-inhibiting activity. More specifically, the method is outlined as follows though more detailed explanations thereof will be made hereinafter in Example 14. When HUVECs are cultured on a  
10 plate coated with Matrigel (Becton Dickinson), vascular endothelial cells form a tube-like structure (Figure 9). When the ChMIL polypeptide purified by the above-mentioned affinity chromatography is added to the culture liquid, the formation of tube-like structure of HUVECs  
15 was inhibited (Figure 9). Therefore, it is clear that ChMIL has a angiogenesis-inhibiting activity, and that the soluble ChMIL polypeptide can be applied as a therapeutic agent for diseases accompanied by angiogenesis such as diabetic retinopathy, cancer, and  
20 rheumatoid arthritis.

Using the polypeptide encoded by the ChMIL gene of the present invention, a specific antibody can be generated. An antigen as used herein includes a  
25 polypeptide produced in large quantities according to the above genetic engineering method or a chemically synthesized polypeptide, and an antibody obtained may be any of polyclonal antibody or monoclonal antibody, and can be effectively used for the purification, measurement, recognition, and the like of said  
30 polypeptide. Hence, polyclonal antibodies and monoclonal antibodies against said polypeptide can be used for treatment or the development of therapeutic methods for diseases that are mediated (directly or indirectly) by said polypeptide, and can also be used as diagnostic  
35 reagents for the above diseases.

Antibodies that specifically bind to the polypeptide encoded by the ChMIL gene of the present invention can be

- 25 -

generated as shown in Example 7. That the generated anti-ChMIL polypeptide antibody specifically binds to said polypeptide was confirmed in the result of Western blot shown in Example 8 (Figure 4).

5       Anti-ChMIL polypeptide antibody may also be used for immunostaining tissue sections as described in Example 11. When a rib cartilage was stained with an anti-ChMIL polypeptide antibody, cells that assume a fibroblast-like flat form occurring in such a way as to surround the  
10       cartilaginous tissue were specifically stained (Figure 7). On the other hand, it has been demonstrated that ChM-I is specifically expressed on chondrocytes and immunostaining has also shown that it is accumulated in the chondrocytes and matrices other than the chondrocytes  
15       (Hiraki et al., J. Biol. Chem., 272, 32429-32426, 1997). It was therefore revealed that ChMIL and ChM-I are expressed in different cells in the tissue including cartilage, which thereby demonstrated that ChMIL and ChM-I are molecules that have different functions.

20       The tissue containing the cell group exhibiting a fibroblast-like form that was demonstrated to be expressing the ChMIL protein by immunostaining is conventionally termed as perichondrium (Suda et al., Bone Formation and Bone Absorption and their regulating  
25       factors 1, 2, 1995). Though there is no definite definition at present on the tissue perichondrium, it is herein intended to mean a tissue containing cell groups that exhibit a fibroblast-like form.

30       The cells present in the perichondrium are thought to be a source for chondrocytes that are required for the development of cartilaginous tissues during the process of endochondral bone formation. Hence, the perichondrium is an important tissue that supplies chondrocytes at the time of skeleton formation during the process of  
35       development or bone and cartilage injuries in adults. Furthermore, though the cartilaginous tissue is characterized in that there are no blood vessels, nerves,

- 26 -

or lymphatic vessels, the perichondrium is thought to regulate the infiltration of blood vessels, nerves, or lymphatic vessels into the chondrocytes since the perichondrium is present at the interface of cartilaginous tissues and other tissues. Thus, though perichondrium is recognized to be an important tissue, it has no definite definition and detailed study has not been made at present. One reason for this that there are no molecules that are perichondrium-specifically expressed have been elucidated at all.

Accordingly, if the presence of molecules that are specifically expressed in the tissue termed as perichondrium surrounding the cartilaginous tissue is demonstrated, it would provide a very important tool in the study of perichondrium and cartilaginous tissues.

The ChM1L of the present invention is the only molecule that was demonstrated to be perichondrium-specifically expressed, and is thought to regulate the infiltration of blood vessels, nerves, or lymphatic vessels into the cartilaginous tissues.

Hence, the discovery of the ChM1L gene and the result of functional analysis of ChM1L included herein is believed to provide, from now on, a new perspective on the etiology and the development of therapeutic methods for diseases in which perichondrium and other ChM1L-expressing tissues including the cartilaginous tissue are involved.

Thus, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, and agents that promote or reduce the expression of the ChM1L gene are considered to be used as therapeutic agents for diseases in which the above ChM1L-expressing cells are involved.

The above expression analysis of mRNA and the result of immunostaining revealed that the ChM1L gene and the polypeptide encoded thereby of the present invention are expressed in the brain, the eyeball, the skeletal muscle,

- 27 -

the thyroid, the whole rib including cartilage, the kidney, the stomach, the trachea, and cells that assume a fibroblast-like flat form occurring in such a way as to surround the cartilaginous tissue. It suggests, therefore, that the ChM1L gene and the polypeptide encoded thereby of the present invention may be involved in diseases associated with the above tissues that have been confirmed to express them, such as diabetic retinopathy, muscular dystrophy, Basedow's disease, chronic kidney failure, stomach cancer, chronic bronchitis, osteoarthritis and rheumatoid arthritis.

Hence, the ChM1L gene and the ChM1L polypeptide of the present invention, antagonists and agonists to ChM1L including antibody that binds to ChM1L, and agents that promote or reduce the expression of the ChM1L gene are considered to be used as therapeutic agents for these diseases.

#### Examples

The present invention will now be explained more specifically with reference to the following examples. It should be noted, however, that the present invention is not limited to these examples.

#### Example 1. Analysis of the ChM1L amino acid sequence

The homology of amino acid residues of ChM-I and ChM1L was compared (Figure 1(a)). The amino acid sequence was represented by one alphabetical letter. ChM1L has a homology with ChM-I throughout the molecule, but it was found that ChM1L has a particularly high homology with the C-terminal of ChM-I that is extracellularly secreted following the processing of ChM-I.

The homology of amino acid sequences of human, mouse and rat ChM1L was compared (Figure 1(b)). The ChM1L polypeptide is composed of 317 amino acids in humans, mice, and rats, but the 300 amino acid residues were identical in the three (about 95%).

- 28 -

The degree of hydrophobicity of ChM-I and ChM1L is shown in the figure (Figure 2). In both of ChM-I and ChM1L, a large hydrophobic peak is observed in the N-terminal end. This hydrophobic region is characteristically observed in the cell membrane-bound proteins, and it was demonstrated that both of ChM1L and ChM-I are type II membrane-bound proteins.

Example 2. Cloning of the ChM1L gene

Using the amino acid sequence (Genbank accession number M16441) of human ChM-I, TBLASTN search was performed for the Expressed sequence tag data base (dbEST) in the DNA data bank of Japan (DDBJ). As a result, an EST file, Genbank accession number A1123839 was detected as a novel gene fragment having a homology with ChM-I.

Using Clontech's Human fetus Marathon-Ready (TM) cDNA, cDNA was amplified by the RACE method according to the instruction attached to the product. Primers were synthesized from the nucleotide sequence obtained from the above dbEST, and ExTaq polymerase (Takara Shuzo) was used according to the instruction attached to the product. Using GeneAmp (TM) PCR System 9700 (PE Applied Biosystems), PCR reaction was carried out for 30 cycles with each cycle comprising 96°C for 30 seconds, 60°C for 30 seconds, and 72°C for one minute, and finally incubated at 72°C for 6 minutes to obtain a PCR reaction mixture. One tenth of the reaction mixture was added, and the second PCR was performed in the same condition.

The PCR product obtained was subjected to electrophoresis on a 1% agarose gel containing ethidium bromide and then the gel was observed under UV irradiation to examine DNA bands. The amplified fragments were excised from the gel, and were purified using QIAquick Gel Extraction Kit (QIAGEN) according to the instruction attached to the product.

The nucleotide sequence of the purified fragment was

- 29 -

determined using a DNA sequencer (ABI PRISM (TM) 310 Genetic Analyzer) of PE Applied Biosystems and ABI PRISM (TM) BigDye Terminator Cycle Sequencing Ready Reaction kit.

5       The nucleotide sequence of human ChM1L cDNA is shown in SEQ ID NO: 1 and its amino acid sequence is shown in SEQ ID NO: 2.

10       Since the amino acid sequence encoded by the human ChM1L gene represented by SEQ ID NO: 1 has a homology with human ChM-I, the gene was decided to be termed as the ChM1L gene (ChM-I like gene).

15       The coding sequence (CDS) of Human ChM1L cDNA was amplified by PCR, electrophoresed on agarose, and then was purified, which was then cloned using pCR-Script (TM) Amp cloning kit (Stratagene) according to the instruction attached to the product. The sequence of the primers used in PCR are shown in SEQ ID NO: 7 (forward primer) and SEQ ID NO: 8 (reverse primer). The ChM1L gene sequence that has been integrated into the vector was  
20       determined using ABI PRISM (TM) 310 Genetic Analyzer of PE Applied Biosystems and ABI PRISM (TM) BigDye Terminator Cycle Sequencing Ready Reaction kit.

25       Using the amino acid sequence (SEQ ID NO: 2) of human ChM1L, TBLASTN search was carried out as described in the above human case. As a result, as a gene fragment that encodes mouse ChM1L, EST file, Genbank accession number AV009191 was detected, and as a gene fragment that encodes rat ChM1L, EST file, Genbank accession number  
30       A1112003 was detected. Using Mouse 11-day Embryo Marathon-Ready (TM) cDNA and Rat Skeletal muscle Marathon-Ready (TM) cDNA by Clontech, sequences of mouse and rat ChM1L genes were determined by the RACE method as described in the isolation of the human ChM1L gene.

35       The nucleotide sequence of mouse ChM1L cDNA is shown in SEQ ID NO: 3 and the amino acid sequence is shown in SEQ ID NO: 4. The nucleotide sequence of rat ChM1L cDNA is shown in SEQ ID NO: 5 and the amino acid sequence is

- 30 -

shown in SEQ ID NO: 6.

The coding sequences (CDS) of mouse and rat ChM1L cDNA were amplified by PCR, and were purified after agarose electrophoresis, which were then cloned using  
5 pCR-Script (TM) Amp cloning kit (Stratagene) according to the instruction attached to the product. The sequences of the primers used in PCR of the mouse gene are shown in SEQ ID NO: 9 (forward primer) and SEQ ID NO: 10 (reverse primer). The sequences of the primers used in PCR of the  
10 rat gene are shown in SEQ ID NO: 11 (forward primer) and SEQ ID NO: 12 (reverse primer). The sequence of the ChM1L gene that was integrated into the vector was determined using ABI PRISM (TM) 310 Genetic Analyzer of PE Applied Biosystems and ABI PRISM (TM) BigDye  
15 Terminator Cycle Sequencing Ready Reaction kit.

The names of human, mouse and rat ChM1L genes constructed in this Example are abbreviated to:

the vector containing the human ChM1L gene: pCR-hChM1L  
20 the vector containing the mouse ChM1L gene: pCR-mChM1L  
the vector containing the rat ChM1L gene: pCR-rChM1L  
Example 3. Construction of vectors containing genes encoding human and mouse ChM1L proteins in which 6 residues of histidine are fused to the C-terminal  
25

The coding sequences (CDS) of human and mouse ChM1L cDNA were amplified by PCR, and were purified after agarose electrophoresis, which were then cloned using pCR-Script SK(+) vector that has been improved so that 6  
30 histidine residues (His tag) may be fused to the C-terminal and pCR-Script (TM) Amp cloning kit (Stratagene) according to the instruction attached to the product. The sequence of the primers used in PCR of the human gene are shown in SEQ ID NO: 7 (forward primer) and SEQ ID NO:  
35 13 (reverse primer). The sequence of the primers used in PCR of the mouse gene are shown in SEQ ID NO: 9 (forward primer) and SEQ ID NO: 14 (reverse primer). That a

- 31 -

nucleotide sequence encoding a protein in which His tags are fused to the C-terminal of ChM1L was determined using ABI PRISM (TM) 310 Genetic Analyzer (PE Applied Biosystems) and ABI PRISM (TM) BigDye Terminator Cycle Sequencing Ready Reaction kit according to the instruction attached to the product. The amino acid sequences of human and mouse ChM1L in which His tags were fused to the C-terminal are shown in SEQ ID NO: 17 and 18, and the nucleotide sequence encoding them are shown in SEQ ID NO: 15 and 16.

The genes encoding the ChM1L protein constructed in this Example in which a His tag was fused are abbreviated to:

the vector containing a gene encoding the protein in which human ChM1L and His tags were fused : pCR-hChM1LHis

the vector containing a gene encoding the protein in which mouse ChM1L and His tags were fused : pCR-mChM1LHis  
Example 4. Construction of expression vectors

In order to express the ChM1L gene in a mammalian cell, CDSs were excised from the above pCR-hChM1L, pCR-mChM1L, pCR-hChM1LHis, and pCR-mChM1LHis with restriction enzymes EcoRI and NotI, were electrophoresed on agarose, and then the desired bands were purified, which were ligated to pcDNA3.1(+) (Invitrogen) and pCAGGS (Gene, 108, 193-200, 1991) using Ligation high (Toyobo) according to the instruction attached to the product. The solutions after the ligation reaction were subjected to transformation using E. coli JM109 competent cells (Takara Shuzo) according to the instruction attached to the product. After purifying the plasmids, the integration of the desired gene was confirmed by restriction enzyme reactions and agarose electrophoresis.

The vectors constructed in this Example are abbreviated to:

pcDNA3.1(+) vectors containing the hChM1L, mChM1L, hChM1LHis and mChM1LHis: pcDNA-hChM1L, pcDNA-mChM1L, pcDNA-hChM1LHis, and pcDNA-mChM1LHis



- 32 -

pcAGGS vectors containing the hChM1L, mChM1L, hChM1LHis and mChM1LHis: pcAGGS-hChM1L, pcAGGS-mChM1L, pcAGGS-hChM1LHis, and pcAGGS-mChM1LHis

Example 5. Construction of vectors that express human soluble ChM1L protein to which a FLAG tag is fused

The FLAG tag (Sigma) as used herein is a hydrophilic marker peptide comprising eight amino acids (Asp Tyr Lys Asp Asp Asp Asp Lys), and the last five amino acids (Asp Asp Asp Asp Lys) is a recognition sequence for enterokinase. The vectors constructed in this Example can express a protein in which the signal sequence of preprotrypsin, a FLAG tag, the C-terminal end of the extracellular region of ChM1L were fused from the N-terminal end. The protein that was expressed using this vector is secreted into the culture liquid as a soluble protein after the signal sequence of preprotrypsin is cleaved, as explained in detail hereinafter in Example 9. Since a FLAG tag is fused to the protein expressed with this vector, the protein can be purified using anti-FLAG antibody (Sigma) and by cleaving the fusion protein with enterokinase, the FLAG tag can also be removed.

A vector was constructed in which a nucleotide sequence (SEQ ID NO: 19, contained in pFLAG-CMV-1 vector manufactured by Sigma) encoding the signal sequence of preprotrypsin and a FLAG tag (SEQ ID NO: 20) from the N-terminal was integrated into the pcAGGS vector (hereinafter referred to as pSF vector). A nucleotide sequence (nucleotide sequence No. 684 to 1020 of SEQ ID NO: 1) encoding the amino acids No. 212 to 317 of human ChM1L represented by SEQ ID NO: 2 and the translation termination codon was amplified by the PCR method, and the amplified product was integrated into the 3'-end of the nucleotide sequence encoding the FLAG tag of the pSF vector. The sequences of primers used for PCR are shown in SEQ ID NO: 21 (forward primer) and SEQ ID NO: 8 (reverse primer). The integration of the sequence of interest into the constructed vector was confirmed using

- 33 -

a ABI PRISM (TM) 310 Genetic Analyzer (PE Applied Biosystems) and ABI PRISM (TM) BigDye Terminator Cycle Sequencing Ready Reaction kit according to the instruction attached to the product. The nucleotide sequence of this Example integrated into the vector is shown in SEQ ID NO: 22, and the amino acid sequence encoded thereby is shown in SEQ ID NO: 23. The vector constructed in this Example will be abbreviated to pSF-shChM1L.

10 Example 6. Expression analysis of ChM1L mRNA  
Expression analysis of ChM1L mRNA in various tissues of  
an adult (10-week old): Figure 3(a)

A 10-week old C57BL/6 mouse was dissected and each tissue was extracted, which was immediately frozen in liquid nitrogen. The frozen tissue was ground into small pieces, and using IOSGEN (Nippon Gene) according to the instruction attached to the product the total RNA of each tissue was obtained. With one µg of total RNA of each tissue as template, 20 µl of cDNA was synthesized using Superscript II preamplification kit (GIBCO BRL) according to the instruction attached to the product. In RT-PCR, the total liquid volume of the reaction system was set at 50 µl, and for each tissue 0.5 µl of cDNA, 0.25 µl of ExTaq polymerase (Takara Shuzo) were used, to which the forward primer (SEQ ID NO: 9) and the reverse primer (SEQ ID NO: 10) were added to a concentration of 0.2 µM. Using GeneAmp (TM) PCR System 9700 (PE Applied Biosystems), PCR amplification was performed for 30 cycles with each cycle comprising 96°C for 30 seconds, 60°C for 30 seconds, and 72°C for one minute. The reaction mixture obtained was subjected to electrophoresis on a 1% agarose gel containing ethidium bromide and then the gel was observed under UV irradiation to examine the expression of ChM1L mRNA in each tissue.

As shown in Figure 3(a), the expression of ChM1L

- 34 -

mRNA in each tissue of an adult mouse was observed in the brain, the eyeball, the skeletal muscle, the whole rib, and the thyroid. The expression of ChM-I in mice has been confirmed in the eyeball, the thymus, the cartilage, and the whole rib. It is therefore clear that ChMIL and ChM-I are expressed in different tissues in the living body, suggesting that their physiological functions are different.

Expression analysis of ChMIL mRNA in various tissues of a fetus (day 17 of gestation): Figure 3(b)

A fetus of C57BL/6 mouse on day 17 of gestation was removed by Caesarean section. Each tissue was taken out, and was immediately frozen in liquid nitrogen. The extraction of total RNA from the frozen tissue, cDNA synthesis, and RT-PCR were performed as described in the above <Expression analysis of ChMIL mRNA in various tissues of an adult mouse>.

As shown in Figure 3(b), the expression of ChMIL mRNA in each tissue of a fetus mouse was observed in the eyeball, the kidney, the stomach, the whole rib, and the trachea. In the fetus, expression in the kidney and the stomach was observed, in which no expression was observed in the adult mouse. It is therefore likely that ChMIL is involved in the development and morphogenesis of these organs, and is also considered to be involved in the repair and regeneration of organs. It was also revealed that ChMIL mRNA is expressed in the trachea.

Expression analysis of ChMIL mRNA during the developmental stage of a fetus: Figure 3(c)

A fetus of C57BL/6 mouse on each day from day 10 of gestation to childbirth was removed by Caesarean section. Each the whole fetuses was frozen in liquid nitrogen. The extraction of total RNA from the frozen fetus, cDNA synthesis, and the implementation of RT-PCR were performed as described in the above <Expression analysis of ChMIL mRNA in various tissues of an adult mouse>.

The analysis of ChM-I mRNA was carried out using a

- 35 -

fusion protein (SEQ ID NO: 23) and a reverse primer (SEQ ID NO: 24) under the same condition as above.

As shown in Figure 3(c), the expression of ChM1L mRNA during the developmental stage of the fetus is very weak on day 10 of gestation and is increased in expression on days 11 to 13. On the other hand, though the expression of ChM-I was also increased as for ChM1L, it exhibited an evidently stronger expression than ChM1L on days 10 and 11 of gestation. It is therefore clear that the expression of ChM1L lags behind ChM-I during the developmental stage of the fetus, and that these molecules have different functions in the fetus development.

Example 7. Generation of anti-ChM1L peptide polyclonal antibody

A peptide having cysteine at the C-terminal of the sequence from 245 to 252 residues shown in SEQ ID NO: 2 of human ChM1L was chemically synthesized. To this synthetic peptide, MBS/KLH (m-maleimidobenzoyl-N-hydroxysuccinimide ester/keyhole limpet hemocyanin, Boehringer Mannheim) was coupled. After the complex was dissolved in physiological saline, an equal amount of Freund's complete adjuvant (FCA) was added, which was sonicated to prepare an emulsion. This emulsion was subcutaneously given to a rabbit as the initial immunization. Four weeks after the initial immunization, a booster immunization was carried out using Freund's incomplete adjuvant (FIA) to the femoral muscle, and thereafter immunization by subcutaneous administration was carried out for four times at an interval of about two weeks or four weeks. During the booster immunization, blood was partially taken from the auricle, and after the final immunization the entire blood was taken and serum was separated. By affinity purification using a peptide column, an anti-ChM1L peptide polyclonal antibody was obtained.



molecular weight was confirmed to be a form in which a N-linked glycosylation.

Example 9. Analysis of soluble human ChM1L recombinant protein by a Western blot method: Figure 5

5       Using the lipofectamine reagent (GIBCO BRL) according to the instruction attached to the product, pCAGGS and pSF-shChM1L were transfected into COS7 cells. After the culture supernatants were subjected to SDS-PAGE on a 12.5% gel, they were transferred to a nitrocellulose  
10       membrane. Anti-FLAG M2 antibody (Sigma) was used as the primary antibody and HRP-labelled anti-mouse IgG antibody (DAKO) was used as the secondary antibody, and the ECLplus reagent (Amersham Pharmacia Biotech) was used according to the instruction attached to the product to  
15       perform color development reaction.

As shown in Figure 5, soluble human ChM1L protein was detected as a single band at around 17-18 kDa.

Example 10. Deglycosylation analysis of ChM1L recombinant protein

20       Using the lipofectamine reagent (GIBCO BRL) according to the instruction attached to the product, pCAGGS-mChM1LHis was transfected into COS7 cells. After PBS saline containing 2% SDS was added to a dish, cells were harvested by a scraper, and the suspension was  
25       heated at 95°C for 60 minutes. The supernatant was treated with SDS-OUT (TM) SDS Precipitation kit (Pierce) to remove SDS. Using the protein solution thus obtained, a deglycosylation was carried out using the Enzymatic  
30       Deglycosylation Kit (BIO RAD) according to the instruction attached to the product to treat the above protein solution with NANase II, O-glycosidase DS and PNGase F. After the reaction mixture was subjected to  
35       SDS-PAGE on a 12.5% gel, it was transferred to a nitrocellulose membrane. Anti-His tag antibody (Invitrogen) was used as the primary antibody and HRP-labelled anti-mouse IgG antibody (Amersham Pharmacia Biotech) was used as the secondary antibody, and the

- 38 -

ECLplus reagent (Amersham Pharmacia Biotech) was used according to the instruction attached to the product to perform color development reaction.

As shown in Figure 6, the band of ChM1L protein at the high molecular weight disappeared only when treated with PNGase F (lanes 2 and 5). It was therefore demonstrated that the ChM1L protein has been modified with a N-linked sugar chain.

Example 11. Analysis of ChM1L protein at cartilago costalis by immunostaining

An about 10-week old C57BL/6 mouse was dissected to remove the whole rib, which was fixed in a 10 mM phosphate buffer (pH 7.4) (PBS) containing 4% paraformaldehyde, embedded in paraffin, and then sections were prepared. Each step of immunostaining was carried out using Histfine SAB-PO(R) kit (Nichirei) according to the instruction attached to the product, of which outline is as follows: After deparaffinization, endogenous peroxidase was digested with a 3% hydrogen peroxide. After washing with PBS followed by blocking with 10% normal goat serum, the above-mentioned anti-ChM1L peptide antibody at a dilution of 1/160 was added and incubated overnight at 4°C. As a negative control, rabbit IgG was used. After biotin-labelled anti-rabbit IgG antibody and peroxidase-labelled streptoavidin were allowed to react, 3,3'-diaminobenzidine/4HCl was added to perform a color development reaction. The nucleus was stained with haematoxylin, enclosed, and then observed.

As shown in Figure 7, ChM1L protein is expressed in cells that assume a fibroblast-like flat form occurring in such a way as to surround the cartilaginous tissue. On the other hand, there were no expressions observed in the cartilage cell in which the expression of ChM-I has been reported.

Example 12. Chromosome mapping of the human ChM1L gene

Using the gene sequence (SEQ ID NO: 1) of human ChM1L, BLASTN search was performed for the entire DDBJ

- 39 -

data from the DNA data bank of Japan (DDBJ). As a result, Genbank accession number AL035608 was detected as the genome sequence of the ChM1L gene. AL035608 is a sequence mapped on chromosome X. It is therefore clear that the human ChM1L gene is present on chromosome X.

Example 13. Purification of a soluble human ChM1L recombinant protein

Using a Lipofectamine reagent (GIBCO BRL) according to the instruction attached to the product, pSF-shChM1L was transfected into COS7 cells, and 48 hours later the culture supernatant was harvested. Using anti-FLAG M2 affinity gel (Sigma), an affinity column was prepared, and the culture supernatant was applied to the column. After washing the column three times in 25 mM Tris-HCl, 150 mM NaCl (pH 7.4), it was eluted with 0.1 M glycine-HCl (pH 3.5), and the eluent was neutralized with a 1/20 volume of 1M Tris-HCl (pH 9.5).

The culture supernatant and the eluent were subjected to SDA-PAGE and then were stained with Coomassie brilliant blue (CBB), the result of which is shown in Figure 8. Though there are a variety of proteins in the culture supernatant (Figure 8, lane 1), soluble human ChM1L protein was confirmed as an about 20 kDa band in the eluent. This revealed that soluble human ChM1L protein was concentrated and purified by the above procedure (Figure 8, lane 2).

Example 14. Study on the effect of inhibiting angiogenesis using human umbilical vein endothelial cells

Human umbilical vein endothelial cells (HUVECs, Clonetics) were cultured in a exclusive medium (EGM (TM)-2 Bullet Kit(TM), Clonetics) for endothelial cells. To a 12-well plate, Growth factor reduced Matrigel (Becton Dickinson) was added to 600  $\mu$ l/well, which was then incubated at 37°C for 30 minutes. Using a heparin-free exclusive medium for endothelial cells diluted 1/8 in the essential medium (EBM (TM)-2, Clonetics) for endothelial cells, a cell suspension containing  $5 \times 10^4$  cells/ml of



- 40 -

HUVECs were prepared.

Each test substance solution was prepared as a solution in which a 1/20 volume of 1M Tris-HCl (pH 9.5) was added to 0.1M glycine-HCl (pH 3.5), and 200  $\mu$ l/well of it was treated. The above buffer and bovine serum albumin (BSA) at 20  $\mu$ g/well as the negative control, platelet factor 4 (PF-4, CHEMICON) at 1 and 10  $\mu$ g/well as the positive control, and the eluted fractions of Example 13 at 10 and 20  $\mu$ g/well as the soluble human ChM1L recombinant protein were treated. Two ml of the cell suspension ( $1 \times 10^5$  cells) and 200  $\mu$ l of the test substance solution were mixed, and seeded into a 12-well plate coated with Growth factor reduced Matrigel. Nine hours later, the formation of tube-like structures was examined and a photograph was taken. The result is shown in Figure 9. In the negative control, HUVECs formed tube-like structures (Figure 9(a) and (b)), but when ChM1L at 20  $\mu$ g/well (Figure 9(d)) was treated the formation of tube-like structures was inhibited as compared to the negative control.

It was therefore revealed that ChM1L has an effect of inhibiting angiogenesis and thus the soluble ChM1L polypeptide can be used as a therapeutic agent for disease accompanied by angiogenesis such as diabetic retinopathy, cancer, and rheumatoid arthritis.

- 41 -

What is claimed is:

1. A human gene encoding a polypeptide that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 2.
- 5 2. A mouse gene encoding a polypeptide that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 4.
3. A rat gene encoding a polypeptide that substantially comprises the amino acid sequence as set  
10 forth in SEQ ID NO: 6.
4. The human gene according to claim 1 having the nucleotide sequence as set forth in SEQ ID NO: 1.
5. The mouse gene according to claim 2 having the nucleotide sequence as set forth in SEQ ID NO: 3.
- 15 6. The rat gene according to claim 3 having the nucleotide sequence as set forth in SEQ ID NO: 5.
7. A polypeptide encoded by a human gene that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 2.
- 20 8. A polypeptide encoded by a mouse gene that substantially comprises the amino acid sequence as set forth in SEQ ID NO: 4.
9. A polypeptide encoded by a rat gene that substantially comprises the amino acid sequence as set  
25 forth in SEQ ID NO: 6.
10. An oligonucleotide probe that hybridizes to at least part of the gene according to any one of claims 1 to 6.
11. A recombinant DNA comprising the gene according  
30 to any one of claims 1 to 6.
12. A transformant transformed with the recombinant DNA according to claim 11.
13. A method of producing a polypeptide encoded by a human, mouse and rat gene which method comprises  
35 culturing the transformant according to claim 12 and harvesting said polypeptide from the culture.
14. A monoclonal antibody that specifically reacts

- 42 -

with the polypeptide according to any one of claims 7 to 9.

5           15. A polyclonal antibody that specifically reacts with the polypeptide according to any one of claims 7 to 9.

          16. A hybridoma that produces the monoclonal antibody according to claim 14 that is obtained by fusing an antibody-producing cell immunized with the polypeptide according to any one of claims 7 to 9 to a myeloma cell.

10           17. A reagent for detecting a gene said reagent comprising the above oligonucleotide probe according to claim 10.

          18. A diagnostic kit that comprises the polypeptide according to any one of claims 7 to 9 and the above monoclonal antibody according to claim 14 and/or the polyclonal antibody according to claim 15.

          19. A pharmaceutical composition comprising a polypeptide according to any one of claims 7 to 9.

20           20. A pharmaceutical composition comprising the monoclonal antibody according to claim 14 or the polyclonal antibody according to claim 15.

          21. A pharmaceutical composition comprising an antisense oligonucleotide that specifically hybridizes to part of the gene according to claims 1 to 6.

25           22. A pharmaceutical composition comprising a nucleic acid that can be used in gene therapy said composition comprising at least part of the gene according to claims 1 to 6.

30           23. The human gene according to claim 1 or 4 characterized in that it is present on chromosome X.

          24. The polypeptide according to claims 7 to 9 wherein said polypeptide is a membrane-bound form.

          25. A gene encoding the membrane-bound polypeptide according to claim 24.

35           26. The polypeptide according to claims 7 to 9 having an effect of inhibiting angiogenesis.

          27. The gene encoding the polypeptide according to

10080600 .032902

- 43 -

claim 26 said polypeptide having an effect of inhibiting angiogenesis.

- 44 -

ABSTRACT

5       A polypeptide having the amino acid sequence as set forth in SEQ ID NO: 2, 4, or 6, a DNA encoding the same, and an antibody against said polypeptide, and the use thereof. The above amino acid sequence has a homology with chondromodulin-I that has an effect of controlling the growth and differentiation of chondrocytes and inhibiting angiogenesis.

# Fig.1A

hChM-I : human ChM-I  
hChM1L : human ChM1L

```
hChM-I      MTENSDKVPIALVGPDDVEFCSPPAYATLTVKPSSPARLLKVGAVVLISGAVLLLFGAIG
hChM1L      -----MAKNPPENCEDCHILNAEAFKSK--ICKSLKICGLVFGILALTIVLFWG
              *   *   *   *   *   *   *   *   *   *   *   *   *

hChM-I      APYFWKGSDSHIYNVHYTMSINGKLQDGSMEIDAGNNLETFKMGSGAEEAIAVNDQNGI
hChM1L      SKHFWEVPKKAYDMEHTFYSNGEKKIYMEIDPVTRTEIFRSGNGTDETLEVHDFKNKY
              **       *   *   *   *   *   *   *   *   *   *   *

hChM-I      TGIRFAGGEKCYIKAQVKARIPEVGAVTKQSISSKLEGKIMPVKYEENSLIWVAVDQPVK
hChM1L      TGIYFVGLQKCFIKTIQKV-IPEFSEPEEEID----ENEEIITTFEQSVIWPVPAEKPIE
              *** *   *   *   *   *   *   *   *   *   *   *   *

hChM-I      DNSFLS-SKVLELCGDLPIFWLKPTYP--KEIQRRERREVVRKIVPTTTKRP HSGPRSNPG
hChM1L      NRDFLKNSKILEICDNVTMYWINPTLISVSELQDFEEEGEDLHFPANEKKGIEQNEQWVV
              **   *   *   *   *   *   *   *   *   *   *   *

hChM-I      AGR LNNETRPSVQEDSQAFNPDNPHYHQEGESMTFDPRLDHEGICCI ECRRSYTHCQKIC
hChM1L      PQVKVEXTRHAR----QASEEELPINDYTENGIEFDPMLDERGYCCIIYCRGNRYCRRVC
              **       **       *   *   *   *   *   *   *   *

hChM-I      EPLGGYYPWPYNYQGCRSACRVIMPCSWWVARILGMV
hChM1L      EPLLGYYPYPCYQGRVICRVIMPCNWWVARMIGRV
              *** *   *   *   *   *   *   *   *   *   *   *
```

## Fig.1B

hChM1L : human ChM1L

mChM1L : mouse ChM1L

rChM1L : rat ChM1L

```
mChM1L      MAKNPENCEGCHILNAEALKSKKICKSLKICGLVFGILALTLIVLFWGSKHFWPEVSKK
rChM1L      MAKNPENCEGCHILNAEALKSKKIRKSLKICGLVFGILALTLIVLFWGSKHFWPEVSKK
hChM1L      MAKNPENCEDCHILNAEAFKSKKICKSLKICGLVFGILALTLIVLFWGSKHFWPEVPKK
*****

mChM1L      TYDMEHTFYSNGEKKKIYMEIDPITRTEIFRSGNGTDETLEVHDFKNGYTGIFYVGLQKC
rChM1L      TYGMEHTFYSNGEKKKISMEIDPITRTEIFRSGNGTDETLEVHDFKNGYTGIFYVGLQKC
hChM1L      AYDMEHTFYSNGEKKKIYMEIDPVTRTEIFRSGNGTDETLEVHDFKNGYTGIFYVGLQKC
* *****

mChM1L      FIKTQIKVIEFSEPEEEIDENEEITTTFFEQSVIWWPAEKPIENRDFLKNKILEICDN
rChM1L      FIKTQIKVIEFSEPEEEIDENEEITTTFFEQSVIWWPAEKPIENRDFLKNKILEICDN
hChM1L      FIKTQIKVIEFSEPEEEIDENEEITTTFFEQSVIWWPAEKPIENRDFLKNKILEICDN
*****

mChM1L      VTMYWINPTLIASELQDFEEDGEDLHFFTSEKKGIDQNEQWVVPQVKVEKTRHRQASE
rChM1L      VTMYWINPTLIASELQDFEEDGEDLHFFTSEKKGIDQNEQWVVPQVKVEKTRHRQASE
hChM1L      VTMYWINPTLISVSELQDFEEGEDLHFPANEKKGIEQNEQWVVPQVKVEKTRHARQASE
*****

mChM1L      EDLPINDYTENGIEFDPMLDERGYCCICYCRGNRYCRRVCEPLLGYYPYPYCYQGGRVIC
rChM1L      EDLPVNDYTENGIEFDPMLDERGYCCICYCRGNRYCRRVCEPLLGYYPYPYCYQGGRVIC
hChM1L      EELPINDYTENGIEFDPMLDERGYCCICYCRGNRYCRRVCEPLLGYYPYPYCYQGGRVIC
* * *****

mChM1L      RVIMPCNWWVARMGRV
rChM1L      RVIMPCNWWVARMGRV
hChM1L      RVIMPCNWWVARMGRV
*****
```

(a) hChM-I : human ChM-I  
(b) hChM1L : human ChM1L  
(c) mChM1L : mouse ChM1L





Fig.3

- (a) EXPRESSION AT VARIOUS TISSUES OF ADULT (10-WEEK OLD)  
1. BRAIN, 2. EYEBALL, 3. LUNG, 4. THYMUS, 5. HEART, 6. LIVER,  
7. KIDNEY, 8. STOMACH, 9. SPLEEN, 10. SKELETAL MUSCLE, 11.  
WHOLE RIB, 12. FAT, 13. ADRENAL, 14. PITUITARY, 15. THYROID,  
16. INTESTINE
- (b) EXPRESSION AT VARIOUS TISSUES OF FETUS (DAY 17 OF GESTATION)  
1. BRAIN, 2. EYEBALL, 3. LUNG, 4. THYMUS, 5. HEART, 6. LIVER,  
7. KIDNEY, 8. SPLEEN, 9. STOMACH, 10. INTESTINE, 11. WHOLE  
RIB, 12. TRACHEA, 13. PANCREAS
- (c) EXPRESSION DURING THE DEVELOPMENTAL STAGE OF FETUS  
1. DAY 10 OF GESTATION, 2. DAY 11 OF GESTATION, 3. DAY 12 OF  
GESTATION, 4. DAY 13 OF GESTATION, 5. DAY 14 OF GESTATION, 6.  
DAY 15 OF GESTATION, 7. DAY 16 OF GESTATION, 8. DAY 17 OF  
GESTATION, 9. DAY 18 OF GESTATION, 10. DAY OF CHILDBIRTH





Fig. 4

- (a) SDS-PAGE: 1. MOCK, 2. HUMAN ChM1L, 3. MOUSE ChM1L  
(b) SDS-PAGE: 1. MOCK, 2. HUMAN ChM1L(His), 3. MOUSE ChM1L(His)  
(c) WESTERN BLOT (DETECTION WITH ANTI-PEPTIDE ANTIBODY):  
1. MOCK, 2. HUMAN ChM1L, 3. MOUSE ChM1L  
(d) WESTERN BLOT (DETECTION WITH ANTI-His TAG ANTIBODY):  
1. MOCK, 2. HUMAN ChM1L(His), 3. MOUSE ChM1L(His)







Fig. 5

1. Mock
2. soluble human ChM1L




Fig.6

1. NON-TREATED, 2. TREATED WITH NANase II + O-GLYCOSIDASE DS + PNGase F, 3. TREATED WITH NANase II, 4. TREATED WITH O-GLYCOSIDASE DS, AND 5. TREATED WITH PNGase F





Fig.7

(a) RABBIT IgG



(b) ANTI-ChM1L PEPTIDE ANTIBODY




Fig. 8




Fig. 9

(a) Buffer control




(b) BSA (20ug/well)



(c) shChM1L (10ug/well)



(d) shChM1L (20ug/well)



(e) PF-4 (1ug/well)



(f) PF-4 (10ug/well)



# Declaration and Power of Attorney for Patent Application

## 特許出願宣言書および委任状

### Japanese Language Declaration

### 日本語宣言書

私は下記発明者として以下の通り宣言します：

私の住所、郵送先、および国籍は私の氏名の後に記載された通りです。

下記名称の発明に関し請求範囲に記載され特許出願がされている発明内容につき、私が最初、最先かつ唯一の発明者（下記氏名が一つの場合）であるか、あるいは最初、最先かつ共同発明者（下記氏名が複数の場合）であると信じます。

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

下記項目にx印が付いている場合を除き、上記発明の明細書は本書に添付されます。

☐ 上記発明は米国出願番号あるいはPCT国際出願番号（確認番号 \_\_\_\_\_）として \_\_\_\_\_ 年 \_\_\_\_ 月 \_\_\_\_ 日に  
出願され、  
\_\_\_\_\_ 年 \_\_\_\_ 月 \_\_\_\_ 日に補正されました（該当する場合）。

私は特許請求範囲を含み上述の補正で補正された前記明細書の内容を検討し、理解していることをここに表明します。

私は連邦規則法典第 37 編 1 条 56 項に定義される特許性に肝要な情報について開示義務があることを認めます。

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A Novel polypeptide and gene encoding  
the same

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

the specification of which is attached hereto unless the following box is checked:

☒ was filed on September 29, 2000  
as United States Application Number or  
PCT International Application Number  
PCT/JP00/06804 (Conf. No. \_\_\_\_\_)  
and was amended on \_\_\_\_\_  
(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.



## Japanese Language Declaration

## 日本語宣言書

私は米国法典第 35 編 119 条(a)-(d)あるいは 365 条(b)に基づき特許あるいは発明者証書の下記外国出願、または 365 条(a)に基づき米国以外の少なくとも 1 ヶ国を指定した下記 PCT 外国出願についての外国優先権をここに主張するとともに、下記項目に×印を付けることにより優先権を主張する出願以前の出願日を有する特許あるいは発明者証書の外国出願あるいは PCT 外国出願を示します。

## Prior foreign application(s)

外国での先行出願

Priority Claimed  
優先権の主張Yes No  
有り 無し☒ ☐

11-275947 (Pat. Appln.) Japan  
(Number) (Country)  
(番号) (国名)

29 / September / 1999

(Day/Month/Year Filed)  
(出願年月日)☐ ☐

(Number) (Country)  
(番号) (国名)

(Day/Month/Year Filed)  
(出願年月日)

私は米国法典第 35 編 119 条(e)に基づき下記の特許出願の利益をここに主張します。

(Application No.)  
(出願番号)(Filing Date)  
(出願日)(Application No.)  
(出願番号)(Filing Date)  
(出願日)

私は米国法典第 35 編 120 条に基づき下記米国特許出願、あるいは 365 条(d)に基づき米国を指定する下記 PCT 国際特許出願の利益をここに主張し、本特許出願内特許請求範囲の各項目の内容が米国法典第 35 編 112 条の最初の項に規定された方法により先行米国あるいは PCT 国際特許出願で開示されていない限りにおいて連邦規則法典第 37 編 1 条 56 項に定義される特許性に肝要で、先行特許出願の出願日から本特許出願の国内あるいは PCT の出願日までの間に入手された情報について開示義務があることを認めます。

(Application No.)  
(出願番号)(Filing Date)  
(出願日)(Status: patented, pending, abandoned)  
(状態: 特許成立済、係属中、放棄済)(Application No.)  
(出願番号)(Filing Date)  
(出願日)(Status: patented, pending, abandoned)  
(状態: 特許成立済、係属中、放棄済)

私は本宣言書内で私自身の知識に基づいてなされたすべての陳述が真実であり、情報および信ずるところに基づいてなされたすべての陳述が真実であると信じられていることをここに宣言し、さらに故意になされた虚偽の陳述等々は米国法典第 18 編 1001 条に基づき罰金あるいは拘禁または両方による処罰にあたり、またかような故意による虚偽の陳述はそれに基づく特許出願あるいは成立特許の有効性を危うくする可能性があることを認識した上でこれらの陳述をなしたことを宣言します。

I hereby claim foreign priority under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below, and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

I hereby claim the benefit under Title 35, United States Code, § 119(c) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

## Japanese Language Declaration

## 日本語宣言書

委任状：私は下記の米国特許商標局（USPTO）顧客番号のもとに記載される SUGHRUE MION 法律事務所のすべての弁護士を、同顧客番号のもとに記載される個々の弁護士の SUGHRUE MION 法律事務所からの自由裁量に基づき変更され得ることを認識した上で、本特許出願の続きおよびそれに関する特許商標局との業務を遂行する弁護士として指名し、本特許出願に関するすべての通信が同 USPTO 顧客番号のもとに提出された住所宛に送付されることを要請します。

POWER OF ATTORNEY: I hereby appoint all attorneys of SUGHRUE MION, PLLC who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of SUGHRUE MION, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.



23373

PATENT TRADEMARK OFFICE

電話連絡は下記へ：（名前および電話番号）

Direct Telephone Calls to: (name and telephone number)

SUGHRUE MION, PLLC  
(202) 293-7060

SUGHRUE MION, PLLC  
(202) 293-7060

Full name of sole or first inventor 唯一あるいは第一の発明者名 1-00 Kei Yamana	
Inventor's signature 発明者の署名 Kei Yamana	Date 日付 March 12, 2002
Residence 住所 Hino-shi, Tokyo, Japan JPK	
Citizenship 国籍 Japanese	
Mailing Address 郵送先 C/O TEIJIN LIMITED, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065, Japan	
Full name of second joint inventor, if any 第二の共同発明者名 (該当する場合) 2-00 Yukimi Nagasawa	
Second inventor's signature 第二発明者の署名 Yukimi Nagasawa	Date 日付 March 12, 2002
Residence 住所 Hino-shi, Tokyo, Japan JPK	
Citizenship 国籍 Japanese	
Mailing Address 郵送先 C/O TEIJIN LIMITED, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065, Japan	

## 3-00 Full name of third joint inventor, if any

第三の共同発明者名 (該当する場合)

Hitoshi Wada

Third inventor's signature

Date

第三発明者の署名

日付

March 12, 2002

Residence

住所

Hino-shi, Tokyo, Japan JPX

Citizenship

国籍

Japanese

Mailing Address

郵送先

c/o TEIJJIN LIMITED, Tokyo Research Center,  
3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065, Japan

## 4-00 Full name of fourth joint inventor, if any

第四の共同発明者名 (該当する場合)

Yoshinori Kasahara

Fourth inventor's signature

Date

第四発明者の署名

日付

March 12, 2002

Residence

住所

Hino-shi, Tokyo, Japan JPX

Citizenship

国籍

Japanese

Mailing Address

郵送先

c/o TEIJJIN LIMITED, Tokyo Research Center,  
3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065, Japan

## Full name of fifth joint inventor, if any

第五の共同発明者名 (該当する場合)

Fifth inventor's signature

Date

第五発明者の署名

日付

Residence

住所

Citizenship

国籍

Mailing Address

郵送先

## Full name of sixth joint inventor, if any

第六の共同発明者名 (該当する場合)

Sixth inventor's signature

Date

第六発明者の署名

日付

Residence

住所

Citizenship

国籍

Mailing Address

郵送先

## SEQUENCE LISTING

<110> Teijin Limited

<120> A NOVEL POLYPEPTIDE AND GENE ENCODING THE SAME

<130> Q69170

<150> PCT/JP00/06804

<151> 2000-09-29

<150> JP 11-275947

<151> 1999-09-29

<160> 25

<170> PatentIn version 3.1

<210> 1

<211> 1200

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (67)..(1020)

<223>

<400> 1

ctccacctca gcagggtgtct ctccagtcctc tcaaagcaag gaaagagtag tgtgtgctga 60

gagacc atg gca aag aat cct cca gag aat tgt gaa gac tgt cac att 108

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Asp Cys His Ile

1 5 10

cta aat gca gaa gct ttt aaa tcc aag aaa ata tgt aaa tca ctt aag 156

Leu Asn Ala Glu Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys

15 20 25 30

att tgt gga ctg gtg ttt ggt atc ctg gcc cta act cta att gtc ctg 204

Ile Cys Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu

35 40 45

ttt tgg ggg agc aag cac ttc tgg ccg gag gta ccc aaa aaa gcc tat 252

Phe Trp Gly Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr

50 55 60

gac atg gag cac act ttc tac agc aat gga gag aag aag aag att tac 300

Asp Met Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr

65 70 75

atg gaa att gat cct gtg acc aga act gaa ata ttc aga agc gga aat 348

Met Glu Ile Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn

80 85 90

ggc act gat gaa aca ttg gaa gta cac gac ttt aaa aac gga tac act 396

Gly Thr Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr

95 100 105 110

ggc atc tac ttc gtg ggt ctt caa aaa tgt ttt atc aaa act cag att Gly Ile Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile 115 120 125	444
aaa gtg att cct gaa ttt tct gaa cca gaa gag gaa ata gat gag aat Lys Val Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn 130 135 140	492
gaa gaa att acc aca act ttc ttt gaa cag tca gtg att tgg gtc cca Glu Glu Ile Thr Thr Thr Phe Glu Glu Gln Ser Val Ile Trp Val Pro 145 150 155	540
gca gaa aag cct att gaa aac cga gat ttt ctt aaa aat tcc aaa att Ala Glu Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile 160 165 170	588
ctg gag att tgt gat aac gtg acc atg tat tgg atc aat ccc act cta Leu Glu Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu 175 180 185 190	636
ata tca gtt tct gag tta caa gac ttt gag gag gag gga gaa gat ctt Ile Ser Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu 195 200 205	684
cac ttt cct gcc aac gaa aaa aaa ggg att gaa caa aat gaa cag tgg His Phe Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp 210 215 220	732
gtg gtc cct caa gtg aaa gta gag aag acc cgt cac gcc aga caa gca Val Val Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala 225 230 235	780
agt gag gaa gaa ctt cca ata aat gac tat act gaa aat gga ata gaa Ser Glu Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu 240 245 250	828
ttt gat ccc atg ctg gat gag aga ggt tat tgt tgt att tac tgc cgt Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg 255 260 265 270	876
cga gcc aac cgc tat tgc cgc cgc gtc tgt gaa cct tta cta ggc tac Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr 275 280 285	924
tac cca tat cca tac tgc tac caa gga gga cga gtc atc tgt cgt gtc Tyr Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val 290 295 300	972
atc atg cct tgt aac tgg tgg gtg gcc cgc atg ctg ggg agg gtc taa Ile Met Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val 305 310 315	1020
taggagggtt gagctcaaat gcttaaaactg ctggcaacat ataataaatg catgctatcc	1080
aatgaatttc tgcctatgag gcatctggcc cctggtagcc agctctccag aattacttgt	1140
aggtaattcc tctcttcatg ttctaataaa cttctacatt atcaccaaaa aaaaaaaaaa	1200

<211> 317  
 <212> PRT  
 <213> Homo sapiens

<400> 2

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Asp Cys His Ile Leu Asn  
 1 5 10 15

Ala Glu Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys  
 20 25 30

Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp  
 35 40 45

Gly Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr Asp Met  
 50 55 60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu  
 65 70 75 80

Ile Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr  
 85 90 95

Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile  
 100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val  
 115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu  
 130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu  
 145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu  
 165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ser  
 180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His Phe  
 195 200 205

Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val  
 210 215 220

Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu  
225 230 235 240

Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp  
245 250 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly  
260 265 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro  
275 280 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met  
290 295 300

Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val  
305 310 315

<210> 3  
<211> 1180  
<212> DNA  
<213> Mus musculus

<220>  
<221> CDS  
<222> (59)..(1012)  
<223>

<400> 3  
agcagtagtc ctctcagtc tctcaaagca gggaaagagc accgtgtgct gggagacc 58

atg gca aag aat cct cca gag aac tgt gag ggc tgt cac att cta aat 106  
Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile Leu Asn  
1 5 10 15

gca gaa gct ctg aaa tct aag aag ata tgt aaa tca ctg aag att tgt 154  
Ala Glu Ala Leu Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys  
20 25 30

gga cta gtg ttt ggt atc ctg gcc tta act cta att gtc ctg ttt tgg 202  
Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp  
35 40 45

ggg agc aaa cac ttc tgg ccc gag gta tcc aag aaa acc tat gac atg 250  
Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr Asp Met  
50 55 60

gag cac act ttc tac agc aac ggc gag aag aag aag att tac atg gaa 298  
Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu  
65 70 75 80

att gat ccc ata acc aga gaa ata ttc aga agt gga aat ggc act	346
Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr	
85 90 95	
gat gaa aca ttg gaa gtc cat gac ttt aaa aat gga tac act ggc atc	394
Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile	
100 105 110	
tac ttt gta ggt ctt caa aaa tgc ttt att aaa act caa atc aaa gtg	442
Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val	
115 120 125	
att cct gaa ttt tct gaa cca gag gaa gaa ata gat gag aat gaa gaa	490
Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu	
130 135 140	
att act aca act ttc ttt gaa cag tca gtg att tgg gtt ccc gca gaa	538
Ile Thr Thr Thr Phe Glu Glu Gln Ser Val Ile Trp Val Pro Ala Glu	
145 150 155 160	
aag cct att gaa aac aga gac ttc ctg aaa aat tct aaa att ctg gag	586
Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu	
165 170 175	
att tgc gat aat gtg acc atg tac tgg atc aat ccc act cta ata gca	634
Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala	
180 185 190	
gtt tca gaa tta cag gac ttt gag gag gac ggt gaa gat ctt cac ttt	682
Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu His Phe	
195 200 205	
cct acc agt gaa aaa aag ggg att gac cag aat gag caa tgg gtg gtc	730
Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp Val Val	
210 215 220	
ccg caa gtg aag gtg gag aag acc cgc cac acc aga caa gca agc gag	778
Pro Gln Val Lys Val Glu Lys Thr Arg His Thr Arg Gln Ala Ser Glu	
225 230 235 240	
gaa gac ctt cct ata aat gac tat act gaa aat gga att gaa ttt gac	826
Glu Asp Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp	
245 250 255	
cca atg ctg gat gag aga ggt tac tgt tgt att tac tgt cgt cga ggc	874
Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly	
260 265 270	
aac cgt tac tgc cgc cgt gtc tgt gaa cct tta cta ggc tac tac cca	922
Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro	
275 280 285	
tac ccc tac tgc tac caa gga ggt cga gtc atc tgt cgt gtc atc atg	970
Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met	
290 295 300	
cct tgc aac tgg tgg gtg gcc cgc atg ctt ggg aga gtc taa	1012
Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val	
305 310 315	



taggaagatt gagttcaaac gcttaacctt ctgtagcca atatataatt aatgcacgct 1072  
 acctecatgaa ttctctgcta tgaggcatit gcctccaagt agcctatcct tcagaattac 1132  
 ttgtaggata ttctctctct catgttctaa taaacttcta catcatca 1180

<210> 4  
 <211> 317  
 <212> PRT  
 <213> Mus musculus

<400> 4

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile Leu Asn  
 1 5 10 15

Ala Glu Ala Leu Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys  
 20 25 30

Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp  
 35 40 45

Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr Asp Met  
 50 55 60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu  
 65 70 75 80

Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr  
 85 90 95

Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile  
 100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val  
 115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu  
 130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu  
 145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu  
 165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala  
 180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu His Phe  
195 200 205

Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp Val Val  
210 215 220

Pro Gln Val Lys Val Glu Lys Thr Arg His Thr Arg Gln Ala Ser Glu  
225 230 235 240

Glu Asp Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp  
245 250 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly  
260 265 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro  
275 280 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met  
290 295 300

Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val  
305 310 315

<210> 5

<211> 1197

<212> DNA

<213> Rattus norvegicus

<220>

<221> CDS

<222> (68)..(1021)

<223>

<400> 5

actccacctc agcagtggtc tctcagtcct ctcaaagcaa ggaaagagca ctgtgtgctg 60

ggagacc atg gca aag aat cct cca gag aac tgt gag gcc tgt cac att 109  
Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile  
1 5 10

cta aat gca gaa gct ctg aaa tct aag aag ata cgt aaa tca ctg aag 157  
Leu Asn Ala Glu Ala Leu Lys Ser Lys Lys Ile Arg Lys Ser Leu Lys  
15 20 25 30

att tgt gga cta gtg ttt ggt atc ctg gcc tta act cta att gtc ctg 205  
Ile Cys Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu  
35 40 45

ttt tgg ggg agc aaa cac ttc tgg ccc gag gta tcc aag aag acc tat	253
Phe Trp Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr	
50 55 60	
ggc atg gag cac act ttc tac agc aat ggc gag aag aag att tcc	301
Gly Met Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Ser	
65 70 75	
atg gaa att gat ccc ata acc aga aca gaa ata ttc aga agt gga aat	349
Met Glu Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn	
80 85 90	
ggc acc gat gaa aca ttg gaa gtc cat gac ttt aaa aac gga tac act	397
Gly Thr Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr	
95 100 105 110	
ggc atc tac ttt gta ggt ctt caa aaa tgc ttt att aaa act caa atc	445
Gly Ile Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile	
115 120 125	
aaa gtg att cct gaa ttt tct gaa cca gaa gag gaa ata gat gag aat	493
Lys Val Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn	
130 135 140	
gaa gaa att act aca acg ttc ttt gaa cag tca gtg att tgg gtt cct	541
Glu Glu Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro	
145 150 155	
gca gaa aag cct att gaa aac aga gac ttc ctg aaa aat tct aaa att	589
Ala Glu Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile	
160 165 170	
ctg gag att tgc gac aat gtg act atg tac tgg atc aat ccc act cta	637
Leu Glu Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu	
175 180 185 190	
ata gca gtt tca gaa tta cag gac ttt gag gag gat ggt gaa gat ctt	685
Ile Ala Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu	
195 200 205	
cac ttt cct acc agc gaa aaa aaa ggg att gac cag aat gag caa tgg	733
His Phe Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp	
210 215 220	
gtg gtc cca caa gtg aag gtg gag aag acc cgc cgc acc aga caa gca	781
Val Val Pro Gln Val Lys Val Glu Lys Thr Arg Arg Thr Arg Gln Ala	
225 230 235	
agc gag gaa gac ctt cct gtt aat gac tat act gaa aat gga atc gaa	829
Ser Glu Glu Asp Leu Pro Val Asn Asp Tyr Thr Glu Asn Gly Ile Glu	
240 245 250	
ttt gat ccc atg ctg gat gag aga ggt tac tgt tgt att tac tgc cgt	877
Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg	
255 260 265 270	
cga ggc aac cgc tac tgc cgc agg gtc tgt gaa cct tta cta ggc tac	925
Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr	
275 280 285	

tac cca tac ccc tac tgc tac caa gga ggt cga gtc atc tgt cgt gtc 973  
 Tyr Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val  
 290 295 300

atc atg cct tgc aac tgg tgg gtg gcc cgc atg ctt ggg aga gtc taa 1021  
 Ile Met Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val  
 305 310 315

taggaagttt gagtccaaat gcttaacctt ttgttagcca acatataatt aatgcatgct 1081

actccatgaa tttctgcatt tgccctcaag tagcctatcc tccagaatta ttgttaggat 1141

attctctctc tcgtgttcta ataaacgtct acatcatcat caaaaaaaaa aaaaaa 1197

<210> 6  
 <211> 317  
 <212> PRT  
 <213> Rattus norvegicus

<400> 6

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile Leu Asn  
 1 5 10 15

Ala Glu Ala Leu Lys Ser Lys Lys Ile Arg Lys Ser Leu Lys Ile Cys  
 20 25 30

Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp  
 35 40 45

Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr Gly Met  
 50 55 60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Ser Met Glu  
 65 70 75 80

Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr  
 85 90 95

Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile  
 100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val  
 115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu  
 130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu  
 145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu  
165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala  
180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu His Phe  
195 200 205

Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp Val Val  
210 215 220

Pro Gln Val Lys Val Glu Lys Thr Arg Arg Thr Arg Gln Ala Ser Glu  
225 230 235 240

Glu Asp Leu Pro Val Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp  
245 250 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly  
260 265 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro  
275 280 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met  
290 295 300

Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val  
305 310 315

<210> 7  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 7  
gagaccatgg caaagaatcc tccagag

27

<210> 8  
<211> 24  
<212> DNA  
<213> Homo sapiens

<400> 8  
ttagaccctc cccagcatgc gggc

24

<210> 9  
 <211> 27  
 <212> DNA  
 <213> Mus musculus  
  
 <400> 9  
 gagaccatgg caaagaatcc tccagag 27  
  
 <210> 10  
 <211> 24  
 <212> DNA  
 <213> Mus musculus  
  
 <400> 10  
 ttagactctc ccaagcatgc gggc 24  
  
 <210> 11  
 <211> 27  
 <212> DNA  
 <213> Rattus norvegicus  
  
 <400> 11  
 gagaccatgg caaagaatcc tccagag 27  
  
 <210> 12  
 <211> 24  
 <212> DNA  
 <213> Rattus norvegicus  
  
 <400> 12  
 ttagactctc ccaagcatgc gggc 24  
  
 <210> 13  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 13  
 gaccctccc agcatgcggg c 21  
  
 <210> 14  
 <211> 21  
 <212> DNA  
 <213> Mus musculus  
  
 <400> 14  
 gactctcca agcatgcggg c 21  
  
 <210> 15  
 <211> 975  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>

<221> CDS  
 <222> (1)..(975)  
 <223>

<400> 15  
 atg gca aag aat cct cca gag aat tgt gaa gac tgt cac att cta aat 48  
 Met Ala Lys Asn Pro Glu Asn Cys Glu Asp Cys His Ile Leu Asn  
 1 5 10 15  
 gca gaa gct ttt aaa tcc aag aaa ata tgt aaa tca ctt aag att tgt 96  
 Ala Glu Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys  
 20 25 30  
 gga ctg gtg ttt ggt atc ctg gcc cta act cta att gtc ctg ttt tgg 144  
 Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp  
 35 40 45  
 ggg agc aag cac ttc tgg ccg gag gta ccc aaa aaa gcc tat gac atg 192  
 Gly Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr Asp Met  
 50 55 60  
 gag cac act ttc tac agc aat gga gag aag aag aag att tac atg gaa 240  
 Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu  
 65 70 75 80  
 att gat cct gtg acc aga act gaa ata ttc aga agc gga aat ggc act 288  
 Ile Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr  
 85 90 95  
 gat gaa aca ttg gaa gta cac gac ttt aaa aac gga tac act ggc atc 336  
 Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile  
 100 105 110  
 tac ttc gtg ggt ctt caa aaa tgt ttt atc aaa act cag att aaa gtg 384  
 Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val  
 115 120 125  
 att cct gaa ttt tct gaa cca gaa gag gaa ata gat gag aat gaa gaa 432  
 Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu  
 130 135 140  
 att acc aca act ttc ttt gaa cag tca gtg att tgg gtc cca gca gaa 480  
 Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu  
 145 150 155 160  
 aag cct att gaa aac cga gat ttt ctt aaa aat tcc aaa att ctg gag 528  
 Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu  
 165 170 175  
 att tgt gat aac gtg acc atg tat tgg atc aat ccc act cta ata tca 576  
 Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ser  
 180 185 190  
 gtt tct gag tta caa gac ttt gag gag gag gga gaa gat ctt cac ttt 624  
 Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His Phe  
 195 200 205  
 cct gcc aac gaa aaa aaa ggg att gaa caa aat gaa cag tgg gtg gtc 672  
 Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val  
 12/20

210

215

220

cct caa gty aaa gta gag aag acc cgt cac gcc aga caa gca agt gag 720  
 Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu  
 225 230 235 240

gaa gaa ctt cca ata aat gac tat act gaa aat gga ata gaa ttt gat 768  
 Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp  
 245 250 255

ccc atg ctg gat gag aga ggt tat tgt tgt att tac tgc cgt cga ggc 816  
 Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly  
 260 265 270

aac cgc tat tgc cgc cgc gtc tgt gaa cct tta cta ggc tac tac cca 864  
 Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro  
 275 280 285

tat cca tac tgc tac caa gga gga cga gtc atc tgt cgt gtc atc atg 912  
 Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met  
 290 295 300

cct tgt aac tgg tgg gtg gcc cgc atg ctg ggg agg gtc gct cat cat 960  
 Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val Ala His His  
 305 310 315 320

cat cat cat cat taa 975  
 His His His His

<210> 16  
 <211> 324  
 <212> PRT  
 <213> Homo sapiens

<400> 16

Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Asp Cys His Ile Leu Asn  
 1 5 10 15

Ala Glu Ala Phe Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys  
 20 25 30

Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp  
 35 40 45

Gly Ser Lys His Phe Trp Pro Glu Val Pro Lys Lys Ala Tyr Asp Met  
 50 55 60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu  
 65 70 75 80

Ile Asp Pro Val Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr  
 85 90 95



Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile  
100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val  
115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu  
130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu  
145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu  
165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ser  
180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Glu Gly Glu Asp Leu His Phe  
195 200 205

Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp Val Val  
210 215 220

Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala Ser Glu  
225 230 235 240

Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp  
245 250 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly  
260 265 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro  
275 280 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met  
290 295 300

Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val Ala His His  
305 310 315 320

His His His His

<210> 17  
 <211> 975  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> CDS  
 <222> (1)..(975)  
 <223>

<400> 17  
 atg gca aag aat cct cca gag aac tgt gag ggc tgt cac att cta aat 48  
 Met Ala Lys Asn Pro Pro Glu Asn Cys Glu Gly Cys His Ile Leu Asn  
 1 5 10 15

gca gaa gct ctg aaa tct aag aag ata tgt aaa tca ctg aag att tgt 96  
 Ala Glu Ala Leu Lys Ser Lys Lys Ile Cys Lys Ser Leu Lys Ile Cys  
 20 25 30

gga cta gtg ttt ggt atc ctg gcc tta act cta att gtc ctg ttt tgg 144  
 Gly Leu Val Phe Gly Ile Leu Ala Leu Thr Leu Ile Val Leu Phe Trp  
 35 40 45

ggg agc aaa cac ttc tgg ccc gag gta tcc aag aaa acc tat gac atg 192  
 Gly Ser Lys His Phe Trp Pro Glu Val Ser Lys Lys Thr Tyr Asp Met  
 50 55 60

gag cac act ttc tac agc aac ggc gag aag aag aag att tac atg gaa 240  
 Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu  
 65 70 75 80

att gat ccc ata acc aga aca gaa ata ttc aga agt gga aat ggc act 288  
 Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr  
 85 90 95

gat gaa aca ttg gaa gtc cat gac ttt aaa aat gga tac act ggc atc 336  
 Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile  
 100 105 110

tac ttt gta ggt ctt caa aaa tgc ttt att aaa act caa atc aaa gtg 384  
 Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val  
 115 120 125

att cct gaa ttt tct gaa cca gag gaa gaa ata gat gag aat gaa gaa 432  
 Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu  
 130 135 140

att act aca act ttc ttt gaa cag tca gtg att tgg gtt ccc gca gaa 480  
 Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu  
 145 150 155 160

aag cct att gaa aac aga gac ttc ctg aaa aat tct aaa att ctg gag 528  
 Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu  
 165 170 175

att tgc gat aat gtg acc atg tac tgg atc aat ccc act cta ata gca 576  
 Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala  
 15/20

180	185	190	
gtt tca gaa tta cag gac	ttt gag gag gac ggt gaa gat	ctt cac ttt	624
Val Ser Glu Leu Gln Asp	Phe Glu Glu Asp Gly Glu Asp	Leu His Phe	
195	200	205	
cct acc agt gaa aaa aag	ggg att gac cag aat gag	caa tgg gtg gtc	672
Pro Thr Ser Glu Lys Lys	Gly Ile Asp Gln Asn Glu	Gln Trp Val Val	
210	215	220	
cgc caa gtg aag gtg gag	aag acc cgc cac acc aga	caa gca agc gag	720
Pro Gln Val Lys Val Glu	Lys Thr Arg His Thr Arg	Gln Ala Ser Glu	
225	230	235	240
gaa gac ctt cct ata aat	gac tat act gaa aat gga	att gaa ttt gac	768
Glu Asp Leu Pro Ile	Asn Asp Tyr Thr Glu	Asn Gly Ile Glu Phe Asp	
245	250	255	
cca atg ctg gat gag aga	ggg tac tgt tgt att tac	tgt cgt cga ggc	816
Pro Met Leu Asp Glu Arg	Gly Tyr Cys Cys Ile Tyr	Cys Arg Arg Gly	
260	265	270	
aac cgt tac tgc cgc cgt	gtc tgt gaa cct tta cta	ggc tac tac cca	864
Asn Arg Tyr Cys Arg Arg	Val Cys Glu Pro Leu Leu	Gly Tyr Tyr Pro	
275	280	285	
tac ccc tac tgc tac caa	gga ggt cga gtc atc tgt	cgt gtc atc atg	912
Tyr Pro Tyr Cys Tyr Gln	Gly Gly Arg Val Ile Cys	Arg Val Ile Met	
290	295	300	
cct tgc aac tgg tgg gtg	gcc cgc atg ctt ggg aga	gtc gct cat cat	960
Pro Cys Asn Trp Trp Val	Ala Arg Met Leu Gly Arg	Val Ala His His	
305	310	315	320
cat cat cat cat taa			975
His His His His			

<210> 18  
 <211> 324  
 <212> PRT  
 <213> Mus musculus

<400> 18

Met Ala Lys Asn Pro	Pro Glu Asn Cys	Glu Gly Cys His Ile	Leu Asn
1	5	10	15

Ala Glu Ala Leu Lys	Ser Lys Lys Ile	Cys Lys Ser Leu	Lys Ile Cys
20	25	30	

Gly Leu Val Phe Gly	Ile Leu Ala Leu Thr	Leu Ile Val Leu Phe Trp
35	40	45

Gly Ser Lys His Phe Trp	Pro Glu Val Ser Lys	Lys Thr Tyr Asp Met
50	55	60

Glu His Thr Phe Tyr Ser Asn Gly Glu Lys Lys Lys Ile Tyr Met Glu  
65 70 75 80

Ile Asp Pro Ile Thr Arg Thr Glu Ile Phe Arg Ser Gly Asn Gly Thr  
85 90 95

Asp Glu Thr Leu Glu Val His Asp Phe Lys Asn Gly Tyr Thr Gly Ile  
100 105 110

Tyr Phe Val Gly Leu Gln Lys Cys Phe Ile Lys Thr Gln Ile Lys Val  
115 120 125

Ile Pro Glu Phe Ser Glu Pro Glu Glu Glu Ile Asp Glu Asn Glu Glu  
130 135 140

Ile Thr Thr Thr Phe Phe Glu Gln Ser Val Ile Trp Val Pro Ala Glu  
145 150 155 160

Lys Pro Ile Glu Asn Arg Asp Phe Leu Lys Asn Ser Lys Ile Leu Glu  
165 170 175

Ile Cys Asp Asn Val Thr Met Tyr Trp Ile Asn Pro Thr Leu Ile Ala  
180 185 190

Val Ser Glu Leu Gln Asp Phe Glu Glu Asp Gly Glu Asp Leu His Phe  
195 200 205

Pro Thr Ser Glu Lys Lys Gly Ile Asp Gln Asn Glu Gln Trp Val Val  
210 215 220

Pro Gln Val Lys Val Glu Lys Thr Arg His Thr Arg Gln Ala Ser Glu  
225 230 235 240

Glu Asp Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu Phe Asp  
245 250 255

Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg Arg Gly  
260 265 270

Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr Tyr Pro  
275 280 285

Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val Ile Met  
290 295 300



<210> 22  
 <211> 432  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> signal sequence of preprotrypsin, FLAG peptide and C terminal region of ChM1L

<220>  
 <221> CDS  
 <222> (1)..(432)  
 <223>

```

<400> 22
atg tct gca ctt ctg atc cta gct ctt gtt gga gct gca gtt gct gac      48
Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
1          5          10          15

tac aaa gac gat gac gac aag ctg gaa ttc gat gag gga gaa gat ctt      96
Tyr Lys Asp Asp Asp Lys Leu Glu Phe Asp Glu Gly Glu Asp Leu
20          25          30

cac ttt cct gcc aac gaa aaa aaa ggg att gaa caa aat gaa cag tgg      144
His Phe Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp
35          40          45

gtg gtc cct caa gtg aaa gta gag aag acc cgt cac gcc aga caa gca      192
Val Val Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala
50          55          60

agt gag gaa gaa ctt cca ata aat gac tat act gaa aat gga ata gaa      240
Ser Glu Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu
65          70          75          80

ttt gat ccc atg ctg gat gag aga ggt tat tgt tgt att tac tgc cgt      288
Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg
85          90          95

cga ggc aac cgc tat tgc cgc cgc gtc tgt gaa cct tta cta ggc tac      336
Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr
100          105          110

tac cca tat cca tac tgc tac caa gga gga cga gtc atc tgt cgt gtc      384
Tyr Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val
115          120          125

atc atg cct tgt aac tgg tgg gtg gcc cgc atg ctg ggg agg gtc taa      432
Ile Met Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val
130          135          140

```

<210> 23  
 <211> 143  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> signal sequence of preprotrypsin, FLAG peptide and C terminal region of ChMIL

<400> 23

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp  
1 5 10 15

Tyr Lys Asp Asp Asp Asp Lys Leu Glu Phe Asp Glu Gly Glu Asp Leu  
20 25 30

His Phe Pro Ala Asn Glu Lys Lys Gly Ile Glu Gln Asn Glu Gln Trp  
35 40 45

Val Val Pro Gln Val Lys Val Glu Lys Thr Arg His Ala Arg Gln Ala  
50 55 60

Ser Glu Glu Glu Leu Pro Ile Asn Asp Tyr Thr Glu Asn Gly Ile Glu  
65 70 75 80

Phe Asp Pro Met Leu Asp Glu Arg Gly Tyr Cys Cys Ile Tyr Cys Arg  
85 90 95

Arg Gly Asn Arg Tyr Cys Arg Arg Val Cys Glu Pro Leu Leu Gly Tyr  
100 105 110

Tyr Pro Tyr Pro Tyr Cys Tyr Gln Gly Gly Arg Val Ile Cys Arg Val  
115 120 125

Ile Met Pro Cys Asn Trp Trp Val Ala Arg Met Leu Gly Arg Val  
130 135 140

<210> 24

<211> 21

<212> DNA

<213> Mus musculus

<400> 24

tcagccatga cagagaactc a

21

<210> 25

<211> 21

<212> DNA

<213> Mus musculus

<400> 25

ttacaccatg cccaagatgc g

21